Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
SCHEDULE
14A Information
Proxy
Statement Pursuant to Section 14(a) of the Securities
Exchange
Act of 1934 (Amendment No. _________)
Filed
by the
Registrant x
|
|
Filed
by a Party other than the Registrant ¨
|
|
Check
the appropriate box:
|
|
|
x
|
Preliminary
Proxy Statement
|
|
|
¨
|
Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
|
¨
|
Definitive
Proxy Statement
|
|
|
¨
|
Definitive
Additional Materials
|
|
|
¨
|
Soliciting
Material Pursuant to Rule 14a-12
|
NUTRACEA
|
(Name
of Registrant as Specified In Its Charter)
|
(Name
of Person(s) Filing Proxy Statement, if other than the
Registrant)
|
|
|
|
Payment
of Filing Fee (Check the appropriate box):
|
|
|
x
|
No
fee required
|
|
|
¨
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(4)
and 0-11
|
|
|
|
|
(1)
|
Title
of each class of securities to which transaction
applies:
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant
to
Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is
calculated and state how it was determined)
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
(5)
|
Total
fee paid:
|
|
|
¨
|
Fee
paid previously with preliminary materials.
|
|
|
¨
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its
filing.
|
|
|
|
|
(1)
|
Amount
Previously Paid:
|
|
(2)
|
Form,
Schedule or Registration Statement No.:
|
|
(3)
|
Filing
Party:
|
|
(4)
|
Date
Filed:
|
PRELIMINARY
COPY
NUTRACEA
5090
North 40th
Street, Fourth Floor
Phoenix,
Arizona 85018
NOTICE
OF ANNUAL MEETING OF SHAREHOLDERS
TO
BE HELD ON JUNE 19, 2007
TO
THE
SHAREHOLDERS:
The
2007
Annual Meeting of Shareholders of NutraCea, a California corporation, will
be
held at the Ritz Carlton, 2401 East Camelback Road, Phoenix, Arizona 85016,
on
Tuesday, June 19, 2007, from 9:00 A.M. to 11:00 A.M., local time, for
the purpose of considering and voting upon:
|
1.
|
the
election of seven directors to serve on the Board of Directors until
the
2008 Annual Meeting of Shareholders or until their successors have
been
duly elected and qualified;
|
|
2.
|
the
approval of an amendment to the 2005 Equity Incentive Plan to provide
for
automatic annual option grants to our non-employee directors;
|
|
3.
|
the
approval of an amendment to our articles of incorporation to increase
the
authorized number of shares of common stock from 200,000,000 to
350,000,000;
|
|
4.
|
the
approval of an amendment to our bylaws to eliminate cumulative voting
for
directors if we become a listed corporation;
and
|
|
5.
|
the
transaction of any other business that is properly presented before
the
annual meeting or any adjournment or postponement
thereof.
|
All
holders of shares of common stock, as of the close of business on April 23,
2007, are entitled to receive notice of, and to vote at, the annual meeting
or
any adjournment or postponement thereof.
All
shareholders are cordially invited to attend the meeting in person. However,
to
assure your representation at the meeting, you are urged to submit your proxy
as
promptly as possible according to the enclosed instructions, whether or not
you
plan to attend the meeting. Any shareholder attending the meeting may vote
in
person even if he or she submitted a proxy.
|
|
By
Order of the
Board of Directors, |
|
|
|
|
|
/s/
TODD C. CROW |
|
|
Todd
C. Crow
|
Phoenix,
Arizona
May
21,
2007
IMPORTANT
Whether
or not you expect to attend the 2007 Annual Meeting of Shareholders
in
person, please complete, date, sign, and return the enclosed proxy
card in
the enclosed envelope, which requires no postage if mailed in the
United
States. Your proxy will be revocable any time prior to its exercise
either
in writing or by voting your shares personally at the 2007 Annual
Meeting
of Shareholders.
|
PRELIMINARY
COPY
NUTRACEA
5090
North 40th
Street, Fourth Floor
Phoenix,
Arizona 85018
FOR
2007
ANNUAL MEETING OF SHAREHOLDERS
This
Proxy Statement is being furnished to holders of common stock, no par value
per
share (the “Common Stock”), of NutraCea, a California corporation (“NutraCea” or
the “Company”), in connection with the solicitation of proxies by the Board of
Directors (“Board”) for use at NutraCea’s Annual Meeting of Shareholders (the
“Annual Meeting”) to be held on June 19, 2007 at 9:00 a.m., local time, or
at any adjournment(s) or postponement(s) thereof, for the purposes set
forth herein and in the accompanying Notice of Annual Meeting of Shareholders.
The Annual Meeting will be held at the Ritz Carlton, 2401 East Camelback Road,
Phoenix, Arizona 85016, on Tuesday, June 19, 2007. The telephone number at
that
address is (602) 468-0700.
These
proxy solicitation materials and NutraCea’s Annual Report to Shareholders for
the year ended December 31, 2006, including financial statements, were mailed
on
or about May 21, 2007 to all shareholders entitled to vote at the Annual
Meeting.
INFORMATION
CONCERNING SOLICITATION AND VOTING
Purposes
of the Annual Meeting
The
purposes of the Annual Meeting are: (i) to elect seven (7) directors
to serve for the ensuing year and until their successors are duly elected and
qualified; (ii) to approve an amendment to the 2005 Equity Incentive Plan
to provide for automatic annual option grants to our non-employee directors;
(iii) to approve an amendment to our articles of incorporation to increase
the
authorized number of shares of common stock from 200,000,000 to 350,000,000;
(iv) to approve an amendment to our bylaws to eliminate cumulative voting for
directors if we become a listed corporation; and (v) to transact such other
business as may properly come before the meeting or any adjournment
thereof.
Shareholders
Entitled to Vote; Record Date
Only
holders of record of Common Stock at the close of business on April 23,
2007 (the “Record Date”) are entitled to notice of and to vote at the Annual
Meeting. As of the Record Date, there were 135,625,849 shares of Common Stock
outstanding.
Any
proxy
given pursuant to this solicitation may be revoked by the person giving it
at
any time before its use by delivering to NutraCea (Attn: Corporate Secretary)
a
written notice of revocation or a duly executed proxy bearing a later date,
or
by attending the Annual Meeting and voting in person. Attending the Annual
Meeting in and of itself will not constitute a revocation of a
proxy.
General.
Your
shares will be voted in accordance with the instructions you indicate when
you
submit your proxy. If you submit a proxy but do not indicate your voting
instructions, your shares will be voted as follows:
|
·
|
FOR
the election of the director nominees listed in this proxy
statement;
|
|
·
|
FOR
the approval of the amendment of the 2005 Equity Incentive Plan;
|
|
·
|
FOR
the approval of the amendment to our articles of incorporation;
|
|
·
|
FOR
the approval of the amendment to our bylaws;
and
|
|
·
|
At
the discretion of the proxy holders, upon such other business as
may
properly come before the Annual Meeting or any adjournment or postponement
thereof.
|
Voting
by Mail. By
signing and returning the enclosed proxy card according to the instructions
provided, you are enabling the individuals named on the proxy card, known as
“proxies,” to vote your shares at the meeting in the manner you indicate. We
encourage you to sign and return the proxy card even if you plan to attend
the
meeting. In this way your shares will be voted even if you are unable to attend
the meeting.
Voting
in Person at the Meeting. If
you plan to attend the Annual Meeting and vote in person, NutraCea will provide
you with a ballot at the meeting. If your shares are registered directly in
your
name, you are considered the shareholder of record, and you have the right
to
vote in person at the meeting. If your shares are held in the name of your
broker or other nominee, you are considered the beneficial owner of shares
held
in your name. In that case, and if you wish to vote at the meeting, you will
need to bring with you to the meeting a legal proxy from your broker or other
nominee authorizing you to vote these shares.
Each
share of Common Stock outstanding on the Record Date entitles its owner to
one
vote on all matters. With respect to the election of directors, every
shareholder voting at the election of directors may cumulate such shareholder’s
votes and give one candidate a number of votes equal to the number of directors
to be elected multiplied by the number of votes to which the shareholder’s
shares are entitled, or distribute the shareholder’s votes on the same principle
among as many candidates as the shareholder thinks fit, provided that votes
cannot be cast for more than six candidates. However, no shareholder shall
be
entitled to cumulate votes unless the candidate’s name has been placed in
nomination prior to the voting and the shareholder, or any other shareholder,
has given notice at the Annual Meeting prior to the voting of the intention
to
cumulate the shareholder’s votes. On all other matters, each share of Common
Stock has one vote.
Expenses
of solicitation of proxies will be borne by NutraCea. NutraCea may reimburse
brokerage firms and other persons representing beneficial owners of shares
for
their expenses in forwarding solicitation materials to such beneficial owners.
Proxies may also be solicited by certain of NutraCea’s directors, officers and
regular employees, without additional compensation, personally or by telephone,
telegram or letter. NutraCea may engage the services of a professional proxy
solicitation firm to aid in the solicitation of proxies from certain brokers,
bank nominees and other institutional owners. NutraCea’s costs for such
services, if retained, will not be material.
Quorum;
Abstentions; Broker Non-votes
A
majority of the shares of Common Stock outstanding on the Record Date and
entitled to vote must be present, in person or represented by proxy, to
constitute the required quorum for the transaction of business at the Annual
Meeting. Shares that are voted “FOR,” “AGAINST,” or “WITHHELD” are treated as
being present at the meeting for purposes of establishing a quorum. Shares
that
are voted “FOR” or “AGAINST” a matter will also be treated as shares entitled to
vote (the “Votes Cast”) with respect to such matter.
A
plurality of Votes Cast is required for the election of directors and only
affirmative votes (either “FOR” or “AGAINST”) will affect the outcome of the
election of directors. Assuming a quorum is present, the affirmative vote of
a
majority of the shares of our common stock represented at the Annual Meeting
is
required to approve the amendment to our 2005 Equity Incentive Plan. The
affirmative vote of a majority in voting power of all of our outstanding shares
of common stock is required to approve the amendment to our articles of
incorporation and the amendment to our bylaws.
While
there is no definitive statutory or case law authority in California as to
the
proper treatment of abstentions or broker “non-votes”, NutraCea believes that
both abstentions and broker “non-votes” should be counted for purposes of
determining the presence or absence of a quorum for the transaction of business.
NutraCea further believes that neither abstentions nor broker “non-votes” should
be counted as shares “represented and voting” with respect to a particular
matter for purposes of determining the total number of Votes Cast with respect
to such matter. In the absence of controlling precedent to the contrary,
NutraCea intends to treat abstentions and broker “non-votes” in this manner.
Accordingly, abstentions and broker “non-votes” will not affect the
determination as to whether the requisite majority of Votes Cast has been
obtained with respect to a particular matter.
A
broker
“non-vote” occurs when a nominee holding shares for a beneficial owner does not
vote on a particular proposal because the nominee does not have discretionary
voting power with respect to that item and has not received instructions from
the beneficial owner. Nominees will not have discretionary voting power with
respect to the proposals to approve the amendment to the 2005 Equity Incentive
Plan, the amendment to the articles of incorporation or the amendment to the
bylaws, and will consequently be unable to vote shares held by beneficial owners
who do not give voting instructions to nominees with respect to this
proposals.
Deadlines
for Submission of Shareholder Proposals for 2008 Annual
Meeting
Requirements
for Shareholder Proposals to be Considered for Inclusion in Proxy
Materials. Shareholders
of NutraCea are entitled to present proposals for consideration at forthcoming
shareholder meetings provided that they comply with the proxy
rules promulgated by the Securities and Exchange Commission or the Bylaws
of NutraCea. Shareholders who wish to have a proposal considered for inclusion
in NutraCea’s proxy materials for NutraCea’s 2008 Annual Shareholder Meeting
must submit such proposal to NutraCea by January 21, 2007. The submission of
a
proposal does not guarantee that it will be included in NutraCea’s proxy
statement or proxy.
Requirements
for Shareholder Proposals not to be Included in Proxy
Materials. Shareholders
who wish to present a proposal at an annual meeting of shareholders that is
not
intended to be included in the proxy materials relating to such meeting must
deliver notice of such proposal to the Secretary of NutraCea at NutraCea’s
principal executive offices by April 6, 2008.
If
you
share an address with another shareholder, you may receive only one set of
proxy
materials (including the annual report and proxy statement) unless you have
previously provided contrary instructions. If you wish to receive a separate
set
of proxy materials, please request the additional copies by writing or
contacting NutraCea’s Chief Financial Officer at 5090 North 40th
Street,
Fourth Floor, Phoenix, Arizona 85018, telephone (602) 522-3000. Similarly,
if
you share an address with another shareholder and have received multiple copies
of the proxy materials, you may contact NutraCea at the address or telephone
number above to request that only a single copy of these materials be delivered
to your address in the future.
ELECTION
OF DIRECTORS
Description
of Current Board of Directors
A
board
of seven (7) directors is to be elected at the meeting. Unless otherwise
instructed, the proxy holders will vote the proxies received by them for the
seven nominees named below, all of whom other than Wesley K. Clark are presently
directors of NutraCea. Mr. Clark has been appointed to the board, effective
as
of June 1, 2007. Our Board of Directors did not nominate Patricia McPeak, one
of
our current directors, for reelection to the Board of Directors. Concurrently
with the Annual Meeting, our by-laws will be amended to reduce the size of
our
Board of Directors from eight (8) members to seven (7) members. In the event
that any such nominee is unable or declines to serve as a director at the time
of the Annual Meeting of Shareholders, the proxies will be voted for any nominee
who shall be designated by the present Board of Directors to fill the vacancy.
In the event that additional persons are nominated for election as directors,
the proxy holders intend to vote all proxies received by them in such a manner
in accordance with cumulative voting as will assure the election of as many
of
the nominees listed below as possible, and, in such event, the specific nominees
to be voted for will be determined by the proxy holders. The seven nominees
for
director receiving the highest number of affirmative votes of the shares
entitled to be voted for them shall be elected as directors. Votes withheld
from
any director are counted for purposes of determining the presence or absence
of
a quorum, but have no other legal effect under California law. It is not
expected that any nominee will be unable or will decline to serve as a director.
The term of office of each person elected as a director will continue until
the
next Annual Meeting of Shareholders or until a successor has been elected and
qualified.
The
names
of the nominees, and certain information about them as of the Record Date,
are
set forth below.
Name
|
|
Age
|
|
Position
|
Bradley
D. Edson
|
|
47
|
|
Chief
Executive Officer, President and Director
|
David
S. Bensol (1)(2)(3)
|
|
51
|
|
Director
and Chairman of the Board
|
Wesley
K. Clark
|
|
62
|
|
Director
|
James
C. Lintzenich (1)(2)
|
|
53
|
|
Director
|
Edward
L. McMillan (1)(3)
|
|
61
|
|
Director
|
Steven
W. Saunders
|
|
51
|
|
Director
|
Kenneth
L. Shropshire (2)(3)
|
|
52
|
|
Director
|
(1)
|
Member
of the Audit Committee.
|
|
|
(2)
|
Member
of the Compensation Committee.
|
|
|
(3)
|
Member
of the Nominating/Governance
Committee.
|
Bradley
D. Edson,
has
served as our Chief Executive Officer since October 2005 and as our President
and as one of our directors since December 2004. Since October 2005, Mr. Edson
also serves as Chief Executive Officer of our subsidiary, The RiceX Company,
and
one of its directors. Mr. Edson was formerly the Chairman and CEO of Vital
Living Inc. (OTC BB: VTLV), a company that primarily developed and marketed
nutraceuticals. Prior to Vital Living, Mr. Edson spent a decade developing
a
nationwide insurance agency focused on distribution channels for specialty
products for the retail market. Prior to that, Mr. Edson was a former principal
and officer of a NASD broker/dealer firm. Mr. Edson holds a Bachelor of Science
Degree in Finance from Arizona State University.
David
S. Bensol,
has
served as one of our directors since March 2005. Mr. Bensol currently is
President of Bensol Realty Corp and a management consultant. Mr. Bensol was
the
former CEO of Critical Home Care, which recently merged with Arcadia Resources,
Inc. (AMEX: KAD) Mr. Bensol was the Executive Vice President and Director of
Arcadia Resources from May 2004 until his resignation from those positions
in
December 2004. In 2000, Mr. Bensol founded what eventually became Critical
Home
Care, through a series of acquisitions and mergers. From 1979 to 1999 Mr. Bensol
founded several public and private companies which became industry leaders
in
the areas of home medical equipment providers, acute care pharmacy providers
and
specialty support surface providers. Mr. Bensol received a BS Pharm. from St.
Johns University, New York, and became a registered pharmacist in
1978.
Wesley
K. Clark, was
appointed to serve as one of our directors, effective as of June 1, 2007. Since
March 2003 he has been the Chairman and Chief Executive Officer of Wesley K.
Clark & Associates, a business services and development firm based in Little
Rock, Arkansas. Mr. Clark also serves as senior advisor to GS Capital
Partners V Fund, L.P. From March 2001 to February 2003 he was a Managing
Director of the Stephens Group Inc., an emerging company development firm.
From
July 2000 to March 2001 he was a consultant for Stephens Group Inc. Prior to
that time, Mr. Clark served as the Supreme Allied Commander of NATO and
Commander-in-Chief for the United States European Command and as the Director
of
the Pentagon’s Strategic Plans and Policy operation. Mr. Clark retired from
the United States Army as a four-star general in July 2000 after 38 years
in the military and received many decorations and honors during his military
career. Mr. Clark is a graduate of the United States Military Academy and
studied as a Rhodes Scholar at the Magdalen College at the University of Oxford.
Mr. Clark is a director of Argyle Security Acquisition Corp. and Summit
Global Logistics, Inc.
James
C. Lintzenich,
has
served as one of our directors since October 2005. Mr. Lintzenich has been
a
director of The RiceX Company since June 2003. Mr. Lintzenich has been a
management consult since April 2001.
From
August 2000 to April 2001 Mr. Lintzenich served as President and Chief Operating
Officer of SLM Corporation (Sallie Mae), an educational loan institution. From
December 1982 to July 2000, Mr. Lintzenich held various senior management and
financial positions including Chief Executive Officer and Chief Financial
Officer of USA Group, Inc., a guarantor and servicer of educational loans.
Mr.
Lintzenich currently serves on the Board of Directors of the Lumina Foundation
for Education.
Edward
L. McMillan,
has
served as one of our directors since October 2005. Mr. McMillan has been a
director of The RiceX Company since July 2004. From January 2000 to present
Mr. McMillan owns and manages McMillan LLC., a transaction consulting firm
which provides strategic consulting services and facilitates mergers and/or
acquisitions predominantly to food and agribusiness industry sectors. From
July
2004 to October 2005, Mr. McMillan was a director of The RiceX Company. From
June 1969 to December 1987 he was with Ralston Purina, Inc. and
Purina Mills, Inc. where he held various senior level management positions
including marketing, strategic planning, business development, product research,
and business segment management. From January 1988 to March 1996,
McMillan was President and CEO of Purina Mills, Inc. From August 1996
to July 1997, McMillan presented a graduate seminar at Purdue University.
From August 1997 to April 1999 he was with Agri Business
Group, Inc. Mr. McMillan currently serves on the boards of directors
of Balchem, Inc. (AMEX:BCP); Durvet, Inc.; Newco
Enterprises, Inc.; CHB LLC.; and Hintzsche, Inc. Mr. McMillan
also serves as Chair of the University of Illinois Research Park, LLC and the
University of Illinois Alumni Association.
Steven
W. Saunders,
has
served as one of our directors since October 2005. He was a director of The
RiceX Company from August 1998 to October 2005. Mr. Saunders has been President
of Saunders Construction, Inc., a commercial construction firm, since February
7, 1991, and President of Warwick Corporation, a business-consulting
firm.
Kenneth
L. Shropshire,
has
served as one of our directors since April 2006. Mr. Shropshire has been a
professor at the Wharton School of the University of Pennsylvania since 1986;
serving as a David W. Hauck professor since 2001, the chair of the Department
of
Legal Studies from 2000 to 2005, and the faculty director of the Sports Business
Initiative since 2004. Mr. Shropshire is currently the president of the Sports
Lawyers Association. Mr. Shropshire was of counsel at the law firm of Van
Lierop, Burns & Bassett, LLP, from 1998 to 2004 and has been a practicing
attorney in Los Angeles, California, focusing on sports and entertainment law.
Mr. Shropshire has also taught coursework at the University of Pennsylvania
School of Law, the University of San Diego School of Law and Southwestern
University School of Law.
Board
Meetings and Committees
During
2006, our board of directors held 14 meetings and each director attended at
least 75% of those meetings.
Our
board
of directors has three standing committees: the Audit Committee, the
Compensation Committee and the Corporate Governance and Nominating Committee.
Our board of directors and its committees set schedules to meet throughout
the
year and also can hold special meetings and act by written consent from time
to
time, as appropriate. Our board of directors has delegated various
responsibilities and authority to its committees as generally described below.
The committees will regularly report on their activities and actions to the
full
board of directors. Each committee of our board of directors has a written
charter approved by our board of directors.
Audit
Committee
The
Audit
Committee assists the full Board of Directors in its general oversight of our
financial reporting, internal controls, and audit functions, and is directly
responsible for the appointment, compensation and oversight of the work of
our
independent registered public accounting firm. The members of the Audit
Committee are James C. Lintzenich, David S. Bensol and
Edward L. McMillan, each an independent director as defined by the
listing standards of the Nasdaq Global Market relating to audit committee
members. The Audit Committee met five times in 2006 and each member of the
Audit
Committee attended all of those meetings. Our board of directors adopted a
written charter for the Audit Committee on April 18, 2007, a copy of which
is
attached as Annex A to this proxy statement. The Board of Directors has
determined that Mr. Lintzenich is an “Audit Committee Financial Expert”, as
defined in Item 401(h) of Regulation S-K.
Compensation
Committee
The
Compensation Committee establishes our executive compensation policy, determines
the salary and bonuses of our executive officers and recommends to the Board
of
Directors stock option grants for our executive officers. The members of the
Compensation Committee are David S. Bensol, James C. Lintzenich and Kenneth
L.
Shropshire, each an independent director as defined by the listing standards
of
the Nasdaq Global Market. In 2006, the Compensation Committee met once and
all
members of the Compensation Committee attended this meetings. Our board of
directors adopted a written charter for the Compensation Committee on April
18,
2007, a copy of which is attached as Annex B to this proxy
statement.
Corporate
Governance and Nominating Committee
The
Corporate Governance and Nominating Committee is responsible for matters
relating to the corporate governance of our company and the nomination of
members of the board of directors and committees thereof. The members of the
Governance and Nominating Committee are David S.
Bensol, Edward L. McMillan and Kenneth L. Shropshire, each an
independent director as defined by the listing standards of the Nasdaq Global
Market. The Corporate Governance and Nominating Committee did not meet in 2006.
Our board of directors adopted a written charter for the Corporate Governance
and Nominating Committee on April 18, 2007, a copy of which is attached as
Annex
C to this proxy statement.
Nomination
Process
In
evaluating potential candidates for membership on the Board, the Corporate
Governance and Nominating Committee may consider such factors as it deems
appropriate. These factors may include judgment, skill, diversity, integrity,
experience with businesses and other organizations of comparable size, the
interplay of the candidate’s experience with the experience of other Board
members and the extent to which the candidate would be a desirable addition
to
the Board and any committees of the Board. While the Corporate Governance and
Nominating Committee has not established any specific minimum qualifications
for
director nominees, the Corporate Governance and Nominating Committee believe
that demonstrated leadership, as well as significant years of service, in an
area of endeavor such as business, law, public service, related industry or
academia, is a desirable qualification for service as a director of NutraCea.
Upon the identification of a qualified candidate, the Corporate Governance
and
Nominating Committee would select, or recommend for consideration by the full
Board, the nominee for the election of directors.
The
Corporate Governance and Nominating Committee will consider nominees recommended
by shareholders. Any shareholder may make recommendations to the Corporate
Governance and Nominating Committee for membership on the Board by sending
a
written statement of the qualifications of the recommended individual to:
Secretary, NutraCea, 5090 North 40th
Street,
Fourth Floor, Phoenix, Arizona 85018. Such recommendations should be received
no
later than sixty (60) days prior to the annual meeting for which the shareholder
wishes his or her recommendation to be considered. The Board will evaluate
candidates recommended by shareholders on the same basis as it evaluates other
candidates, including the following criteria:
|
·
|
Directors
should be of the highest ethical character and share values that
reflect
positively on themselves and
NutraCea.
|
|
·
|
Directors
should have reputations, both personal and professional, consistent
with
the image and reputation of
NutraCea.
|
|
·
|
Directors
should be highly accomplished in their respective fields, with superior
credentials and recognition.
|
The
fact
that a proposed director nominee meets some or all of the above criteria will
not obligate the Corporate Governance and Nominating Committee to nominate
or
recommend the candidate for director in the proxy materials.
Shareholder
Communication Policy
Shareholders
may send communications to the Board or individual members of the Board by
writing to them, care of Secretary, NutraCea, 5090 North 40th
Street,
Fourth Floor, Phoenix, Arizona 85018, who will forward the communication to
the
intended director or directors. If the shareholder wishes the communication
to
be confidential, then the communication should be provided in a form that will
maintain confidentiality.
Attendance
of Directors at Annual Meetings of Shareholders
NutraCea
has a policy of encouraging, but not requiring, directors to attend NutraCea’s
annual meeting of shareholders.
Director
Compensation
Non-employee
directors receive an annual cash retainer of $12,000 and a fee of $1,000 for
each board meeting attended in person and $500 for each telephonic board meeting
attended. In addition, they receive annual retainers of $2,000 per year to
serve
on the audit and compensation committees. The Chairman of the Board receives
an
additional $4,000 per year. The Committee chairmen receive an additional $1,000
per year. Each non-employee director receives an option to purchase 35,000
shares of common stock each year on the date of our Annual Shareholder Meeting.
Directors are reimbursed for reasonable expenses incurred in attending meetings
of the Board and Board committees.
Directors
are eligible to participate in NutraCea’s 2005 Equity Incentive
Plan.
Director
Compensation Table
The
following Director Compensation Table sets forth summary information concerning
the compensation paid to our non-executive officer directors in 2006 for
services to our company.
Name
|
|
Fees Earned
or
Paid in
Cash
($)
|
|
Option
Awards
($)(1)(2)
|
|
All
Other
Compensation ($)
|
|
Total
($)
|
|
David
S. Bensol
|
|
|
21,750
|
|
|
29,223
|
|
|
—
|
|
|
50,983
|
|
Eliot
R. Drell
|
|
|
13,000
|
|
|
29,223
|
|
|
—
|
|
|
42,233
|
|
James
C. Lintzenich
|
|
|
16,750
|
|
|
29,223
|
|
|
—
|
|
|
45,983
|
|
Edward
L. McMillan
|
|
|
17,000
|
|
|
29,223
|
|
|
—
|
|
|
46,233
|
|
Patricia
McPeak
|
|
|
0
|
|
|
—(3
|
)
|
|
155,188(4
|
)
|
|
155,188
|
|
Steven
W. Saunders
|
|
|
14,000
|
|
|
29,223
|
|
|
77,953(5
|
)
|
|
43,223
|
|
Kenneth
L Shropshire
|
|
|
16,750
|
|
|
29,223
|
|
|
—
|
|
|
45,973
|
|
Total
|
|
|
99,250
|
|
|
175,338
|
|
|
233,141
|
|
|
429,816
|
|
(1)
|
Amounts
shown do not reflect compensation actually received by the directors.
Instead, the amounts shown are the compensation costs recognized
by
NutraCea in 2006 for option awards as determined pursuant to Statement
of
Financial Accounting Standards No. 123(R), or FAS 123R. These compensation
costs reflect option awards granted in 2006. The assumptions used
to
calculate the value of option awards are set forth in Note 13 of
the Notes
to Consolidated Financial Statements contained NutraCea’s Annual Report on
Form 10-K for 2006.
|
(2)
|
The
compensation cost recognized by NutraCea in fiscal 2006 for each
stock
option grant is based on the following fair value as of the grant
date:
$39,357 for a stock option grant to each non-employee director to
purchase
35,000 shares of common stock made on May 23, 2006 at an exercise
price of
$1.14 per share. At the end of 2006, Mr. Bensol, Mr. Drell, Mr.
Lintzenich, Mr. McMillan, Ms. McPeak, Mr. Saunders and Mr. Shropshire
held
options to purchase an aggregate of 35,000 shares, 35,000 shares,
35,000
shares, 35,000 shares, 0 shares, 35,000 shares and 35,000 shares,
respectively, as compensation for serving as NutraCea’s directors. Also,
at the end of 2006, Mr. Bensol, Mr. Drell, Mr. Lintzenich, Mr. McMillan,
Ms. McPeak, Mr. Saunders and Mr. Shropshire held an aggregate 0 shares,
35,000 shares, 0 shares, 0 shares, 35,000 shares, 0 shares and 0
shares,
respectively, of common stock received as compensation for serving
as
directors.
|
|
|
(3)
|
Ms.
McPeak did not receive a stock option grant because she is an employee
of
NutraCea.
|
|
|
(4)
|
Reflects
compensation received by Ms. McPeak for serving as an employee of
NutraCea. Compensation consists of the following: $154,807 as salary
and
$381 for payment of life insurance premiums.
|
|
|
(5)
|
Reflects
the grant of a warrant to Mr. Saunders for providing engineering
and
construction consultation to NutraCea. The compensation cost recognized
by
NutraCea in fiscal 2006 for the warrant is based on the following
fair
value as of the grant date: $78,740 for a stock option grant to purchase
100,000 shares of common stock made on February 27, 2006 at an exercise
price of $1.00 per share.
|
Code
of Business Conduct and Ethics
The
Board
has adopted a Code of Business Conduct and Ethics that applies to all directors,
officers and employees of NutraCea. NutraCea will provide any person, without
charge, a copy of this Code. Requests for a copy of the Code may be made by
writing to NutraCea at 5090 North 40th
Street,
Fourth Floor, Phoenix, Arizona 85018, Attention: Chief Financial
Officer.
Recommendation
of the Board
THE
BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF EACH OF THE NOMINATED
DIRECTORS.
Approval
of an amendment to NutraCea’s 2005 Equity Incentive Plan
Shareholders
are being asked to approve an amendment to the 2005 Equity Incentive Plan (“2005
Plan”). On May 26, 2005, the Board adopted the 2005 Plan, and on
September 28, 2005, NutraCea’s shareholders approved the 2005 Plan at a
Special Meeting of Shareholders. As of the Record Date, no awards have been
granted under the 2005 Plan. On April 18, 2007, the Board approved an amendment
to the 2005 Plan to provide for automatic annual stock option grants to
non-employee members of the board of directors. Each option is exercisable
for
35,000 shares of common stock
We
believe strongly that the approval of the amendment to the 2005 Plan (“Plan
Amendment”) is essential to our continued success. Stock options such as those
provided under the 2005 Plan are vital to our ability to attract and retain
outstanding and highly skilled individuals to serve on our board of directors.
In addition, due to recent statutory and regulatory changes, directors are
required to accept greater responsibility, devote more time to their service
as
directors, and in many instances require a specific expertise to serve. The
automatic grant of options to purchase common stock to non-employee directors
under the 2005 Plan reflects the competitive market we must face to attract
and
retain highly competent individuals to our board of directors on whose judgment,
initiative, leadership and continued efforts the growth and profitability of
NutraCea depend.
The
Plan
Amendment provides for option grants to non-employee directors that are
substantially similar to the 35,000 share option grants currently being made
to
non-employee directors separate from the 2005 Plan.
The
following is a summary of the principal provisions of the 2005 Plan. This
summary is qualified in its entirety by reference to the full text of the 2005
Plan, which is attached as Annex D to this proxy statement.
Administration.
The
2005
Plan is administered by the Board, and the Board has delegated administration
to
the Compensation Committee (the “Administrator”). The Administrator acts as the
manager of the 2005 Plan, and as such has the power, subject to the terms and
restrictions set forth in the 2005 Plan, to select the persons (“Participants”)
to receive options (“Options”) or other awards under the 2005 Plan
(collectively, “Awards”), to fix the number of shares that each Participant may
acquire, to set the terms and conditions of each Award (including any vesting
or
exercisability provisions or limitations regarding any Award and/or the shares
of common stock relating thereto, and the waiver, amendment, extension or
acceleration of any such provisions or limitations), and to determine all other
matters relating to the 2005 Plan, subject to applicable law. Determinations
made by the Administrator are final and binding on all parties. The
Administrator may delegate certain authorities and duties to officers or
employees of NutraCea.
Eligibility.
Every
person who at the date on which an Award was granted to the person (the “Grant
Date”) is an employee of NutraCea or any Affiliate is eligible to receive
Awards, including options that are intended to be incentive stock options
(“ISOs”) within the meaning of the Internal Revenue Code of 1986, as amended
(“Code”). The term “Affiliate” means a “parent corporation” or a “subsidiary
corporation” as defined in the applicable provisions of the Code. Every person
who at the Grant Date is a consultant to NutraCea or any Affiliate, or any
person who is a director of NutraCea but not an employee, is eligible to receive
Awards, including non-qualified options (“NQOs”), but is not eligible to receive
ISOs. Employees may also receive NQOs.
Securities
Subject to the 2005 Plan. The
total
number of shares of common stock that are reserved and available for issuance
pursuant to the exercise of Awards under the 2005 Plan is 10,000,000 shares.
In
addition, no more than 10,000,000 shares may be issued as ISOs. No Awards have
been granted under the 2005 Plan. The shares covered by the portion of any
grant
that expires unexercised under the 2005 Plan will become available again for
issuance under the 2005 Plan. The number of shares reserved for issuance under
the 2005 Plan and the number of shares that may be issued as ISOs are subject
to
adjustment in accordance with the provisions for adjustment in the 2005
Plan.
Granting
of Options. No
Options may be granted under the 2005 Plan after 10 years from the date the
Board initially adopted the 2005 Plan. An Option generally expires 10 years
from its Grant Date, unless an earlier expiration date is specified by the
Administrator at the Grant Date, except that an ISO granted to any ten percent
shareholder expires five years from the Grant Date. The exercise price of an
ISO
or an NQO will be determined by the Administrator, and for ISOs must be at
least
equal to the fair market value of the stock covered by the ISO at the Grant
Date
(110% of the fair market value for ISOs granted to a ten percent
shareholder).
Each
Award will be evidenced by a written agreement (in the case of Options, referred
to as the “Option Agreement,” and in the case of other Awards as well as
Options, referred to as the “Award Agreement”), in a form satisfactory to
NutraCea, executed by NutraCea and the Participant to whom the Award is granted.
Provisions of Award Agreements need not be the same for each Participant. Awards
may, in the sole discretion of the Administrator, be exercisable entirely at
the
Grant Date or at such times and in such amounts as the Administrator may
specify.
Automatic
Option Grant Program for Outside Directors.
The 2005 Plan, as amended, provides for automatic option grants for non-employee
directors of NutraCea. The automatic option grant program under the 2005 Plan
(the “Director Program”) provides for the grant of an option to purchase 35,000
shares of common stock to non-employee directors on the date of each annual
shareholder meeting after the director is elected or reelected to our board
of
directors. These option grants generally vest and become exercisable monthly
as
to 1/12th
of the
shares underlying the options until they are fully vested on the first
anniversary of the grant date. The exercise price for Options granted under
the
Director Program is the fair market value of the common stock on the Grant
Date,
and the Options generally expire 10 years from the Grant Date (the “Expiration
Date”). The Options cease to vest if the optionee ceases to be a member of the
Board (the “Termination Date”). If the optionee ceases to be a member of the
Board for any reason, then each Option that has not expired or been exercised
and has vested on the Termination Date may be exercised by the optionee within
90 days after the Termination Date (or such shorter or longer period as
specified in the Option Agreement), but in no event later than the Expiration
Date. All of the current non-employee directors of NutraCea would be eligible
to
receive options under the 2005 Plan. Non-employee directors of NutraCea have
an
interest in the approval of this proposal by virtue of their eligibility to
receive Options under the Director Program.
Corporate
Transactions. The
2005
Plan provides that if NutraCea is merged into or consolidated with another
corporation under circumstances where NutraCea is not the surviving corporation,
is liquidated or dissolved, is the surviving corporation of a merger after
which
the shareholders of NutraCea cease to own their shares or other equity interests
in NutraCea, sells or otherwise disposes of substantially all its assets to
another corporation, or completes any other transaction which qualifies as
a
“corporate transaction” under Section 424(a) of the Code wherein the
shareholders of NutraCea give up all of their equity interest in NutraCea,
the
successor corporation may assume, convert or replace any outstanding Awards.
In
the alternative, the successor corporation may substitute any outstanding Awards
with substantially equivalent Awards or provide substantially similar
consideration to Participants as was provided to shareholders, after taking
into
consideration the existing provisions of the Awards. The successor corporation
may also issue, in place of outstanding Awards of NutraCea held by a
Participant, substantially similar Awards or other property subject to
repurchase restrictions no less favorable to the Participant. If the successor
corporation refuses to assume or substitute outstanding options, such options
will expire on such transaction at such time and on such conditions as the
NutraCea board of directors determines. Options granted under the Director
Program will automatically vest and become exercisable in full in connection
with a corporate transaction described above and the optionee will have
12 months after the Termination Date within which to exercise the option,
as described above.
Payment
of Exercise Price. Except
as
described below, payment in full, in cash, generally must be made for all stock
purchased at the time a written notice of exercise is given to NutraCea.
Proceeds of any such payment will constitute general funds of NutraCea. The
exercise price of options granted under the NutraCea 2005 Plan may be paid
as approved by the Administrator at the time of grant: (a) in cash (by
check); (b) by cancellation of indebtedness of NutraCea to the Participant;
(c) by surrender of shares of common stock owned by the Participant for at
least six months and having a fair market value on the date of surrender equal
to the aggregate exercise price of the option; (d) by waiver of
compensation due to or accrued by the Participant for services rendered;
(e) by a “same-day sale” commitment from the Participant and a National
Association of Securities Dealers, Inc. (“NASD”) broker; (f) by a
“margin” commitment from the Participant and a NASD broker; or (g) by any
combination of the foregoing.
Termination
of Employment. Any
Award
or portion thereof that has not vested on or before the date on which a
Participant ceases, for any reason, with or without cause, to be an employee
or
director of, or a consultant to, NutraCea or an Affiliate (“Employment
Termination”), expires upon the date of Employment Termination. An Award or
portion thereof that has vested as of the date of Employment Termination, to
the
extent the Award has not then expired or been exercised, is exercisable for
a
period of 30 days after the date of Employment Termination or such longer
time period not exceeding five years as the Administrator may determine. If,
however, Employment Termination is due to the disability or death of the
Participant, then the Participant or the Participant’s representative may,
within 12 months after the date of Employment Termination or such shorter
or longer time period not exceeding five years as the Administrator may
determine, exercise such Award rights to the extent they were exercisable on
the
date of Employment Termination.
Restricted
Stock and Bonus Stock. Participants
awarded restricted stock must, within certain time periods specified in the
2005
Plan, pay to NutraCea, if required by applicable law, an amount equal to the
par
value of the Stock subject to the Award. Subject to the provisions of the 2005
Plan and the Award Agreement, during a period set by the Administrator,
commencing with, and not exceeding 10 years from, the date of such Award
(the “Restriction Period”), the Participant may not sell, assign, transfer,
pledge or otherwise encumber shares of restricted stock. Within these limits,
the Administrator may in its discretion provide for the lapse of such
restrictions in installments and may accelerate or waive such restrictions,
in
whole or in part, based on service, performance or such other factors or
criteria as the Administrator may determine. Except to the extent otherwise
provided in the Award Agreement, upon a Participant’s Employment Termination
during the Restriction Period, all shares still subject to restriction will
be
forfeited by the Participant. The 2005 Plan also allows the Administrator to
make Awards of Bonus Stock to a Participant.
Amendment,
Suspension or Termination of the 2005 Plan. The
Board
may at any time amend, alter, suspend or discontinue the 2005 Plan without
shareholder approval, except as required by applicable law; provided, however,
that no amendment, alteration, suspension or discontinuation shall be made
that
would impair the rights of any Participant under any Award previously granted,
without the Participant’s consent, except to conform the 2005 Plan and Awards
granted under the 2005 Plan to the requirements of federal or other tax
laws.
ERISA,
Internal Revenue Code. The
2005
Plan is not subject to the ERISA and is not qualified under
Section 401(a) of the Code.
Summary
of Federal Income Tax Consequences
The
following description of federal income tax consequences associated with
participation in the 2005 Plan is based on current provisions of the Code and
administrative and judicial interpretations thereof. It does not describe
applicable state, local, or foreign tax considerations, nor does it discuss
any
estate or gift tax considerations. The applicable rules are complex and may
vary depending upon a Participant’s individual circumstances. The following
description is thus necessarily general and does not address all of the
potential federal and other income tax consequences to every Participant of
the
2005 Plan or in connection with transactions thereunder.
Incentive
Stock Options
A
Participant will not have taxable income upon the grant or exercise of an ISO.
However, upon exercise, the amount by which the fair market value of the common
stock acquired upon exercise of the Option (“Option Shares”) exceeds the
exercise price of the shares acquired (the “Option Spread”) is included on the
Participant’s “alternative minimum taxable income” in determining the
Participant’s liability for the “alternative minimum tax.” “Alternative minimum
tax” is imposed to the extent it exceeds a Participant’s regular tax liability.
The Option Spread generally is measured for this purpose on the day the Option
is exercised; however, if both (i) the Option Shares are subject to a
“substantial risk of forfeiture” (including a right of repurchase in favor of
NutraCea) and (ii) the Participant does not make an election under
Section 83(b) of the Code with respect to such shares within
30 days after the purchase date (a “Section 83(b) Election”),
then the Option Spread should be measured, and should be included in alternative
minimum taxable income, on the date the risk of forfeiture lapses. NutraCea
receives no income tax deduction upon grant or exercise of an ISO but is
entitled to a deduction equal to the ordinary income taxable to the Participant
upon a Disqualifying Disposition.
In
general, an ISO must be exercised within 90 days of Employment Termination
to retain the federal income tax treatment described above. This 90-day period
does not apply in the case of a Participant who dies while owning an Option.
In
the case of a Participant who is permanently and totally disabled, as defined
in
the Code, this 90-day period is extended to 12 months. The 2005 Plan allows
NutraCea to extend the period during which a Participant may exercise the
Option. In all events, if an Option is exercised more than three months after
Employment Termination, it will, except in the cases of a permanently and
totally disabled or deceased Participant, not qualify as an ISO.
A
Participant generally will be entitled to long-term capital gain treatment
upon
sale (other than to NutraCea) or other disposition of Option Shares held longer
than two years from the grant date and one year from the date the Participant
receives the shares. If the Option Shares are sold or disposed of (including
by
gift, but not including certain tax-free exchanges) before both of these holding
periods have expired (a “Disqualifying Disposition”), the Option Spread (but
generally not more than the amount of gain if the Disqualifying Disposition
is a
sale) is taxable as ordinary income. For this purpose, the Option Spread is
measured at the Exercise Date unless the Option Shares were subject to a
substantial risk of forfeiture upon purchase and the Participant did not
file a Section 83(b) Election, in which event the Option Spread
is measured at the date the restriction lapsed. If gain on a Disqualifying
Disposition exceeds the amount treated as ordinary income, the excess is capital
gain, which will be characterized as long term or short term, depending on
the
holding period. The holding period for Option Shares commences with the Option
exercise date unless the shares are subject to a substantial risk of forfeiture
and no Section 83(b) Election is filed, in which event the holding
period commences with the date the risk lapsed. A sale of common stock to
NutraCea, including use of common stock to pay withholding or withheld by
NutraCea upon exercise of an ISO, will constitute a redemption of such common
stock and may be taxable as a dividend unless certain tests in the Code are
met.
Non-Qualified
Stock Options
A
Participant does not have taxable income upon the grant of a NQO, provided
that
the exercise price is at least equal to the fair market value of the common
stock on the grant date. Federal income tax consequences upon exercise will
depend upon whether the Option Shares thereby acquired are subject to a
substantial risk of forfeiture, described above. If the Option Shares are not
subject to a substantial risk of forfeiture (or if they are subject to such
a
risk and the Participant files a Section 83(b) Election with respect
to the shares), the Participant will have ordinary income at the time of
exercise measured by the Option Spread on the exercise date. The Participant’s
tax basis in the Option Shares will be their fair market value on the date
of
exercise, and the holding period for purposes of determining capital gain or
loss also will begin with the day after transfer. If the Option Shares are
restricted and no Section 83(b) Election is filed, the Participant
will not be taxable upon exercise, but instead will have ordinary income on
the
date the restrictions lapse, in an amount equal to the Option Spread on the
date
of lapse. In such a case, the Participant’s holding period will also begin with
the date of lapse.
Upon
sale
other than to NutraCea of Option Shares acquired under an NQO, a Participant
generally will recognize capital gain or loss to the extent of the difference
between the sale price and the Participant’s tax basis in the shares, which will
be long term or short term depending on the holding period. A sale of shares
to
NutraCea will constitute a redemption of such shares, which may be taxable
as a
dividend.
If
the
exercise price of an NQO is less than the fair market value of the Option Shares
on the date of grant, the Participant recognizes ordinary income as the option
vests in an amount equal to the excess of (i) the fair market value of the
Option Shares on the vesting date, over (ii) the exercise price. In
addition, Section 409A of the Code also imposes a 20% excise tax and an
interest penalty on the amount of such income.
Restricted
Stock and Bonus Stock
Restricted
stock awards and stock bonuses granted under the 2005 Plan generally have the
following federal income tax consequences.
Upon
acquisition of the stock, the recipient normally will recognize taxable ordinary
income equal to the excess, if any, of the stock’s fair market value on the
acquisition date over the purchase price. However, to the extent the stock
is
subject to certain types of vesting restrictions, the taxable event will be
delayed until the vesting restrictions lapse unless the recipient elects under
Section 83(b) of the Code to be taxed on receipt of the stock. With
respect to employees, NutraCea is generally required to withhold from regular
wages or supplemental wage payments an amount based on the ordinary income
recognized. Subject to the requirement of reasonableness, the provisions of
Section 162(m) of the Code and the satisfaction of a tax reporting
obligation, NutraCea will generally be entitled to a business expense deduction
equal to the taxable ordinary income realized by the recipient.
Upon
disposition of the stock, the recipient will recognize a capital gain or loss
equal to the difference between the selling price and the sum of the amount
paid
for such stock plus any amount recognized as ordinary income upon acquisition
(or vesting) of the stock. Such gain or loss will be long-term or short-term
depending on whether the stock was held for more than one year. Slightly
different rules may apply to recipients who acquire stock subject to
certain repurchase options or who are subject to Section 16(b) of the
Exchange Act.
The
grant
of Options or other Awards under the 2005 Plan to executive officers, including
the officers named in the Summary Compensation Table, is subject to the
discretion of the Administrator. As of the date of this Proxy Statement, there
has been no determination by the Administrator with respect to future Awards
under the 2005 Plan. Accordingly, future Awards are not determinable. The table
of option grants under “Executive Compensation” provides information with
respect to the grant of options to the Named Officers during 2006. Assuming
the
approval of the 2005 Plan at the Annual Meeting, options to purchase 35,000
shares of common stock will be awarded to each outside directors under the
2005
Plan other than Wesley Clark. Mr. Clark received an option to purchase 35,000
shares of common stock on May 1, 2007 when he agreed to become a member of
our
board of directors, effective June 1, 2007. Accordingly, he will not receive
a
separate grant this year under the 2005 Plan.
Recommendation
of the Board of Directors
THE
BOARD RECOMMENDS A VOTE FOR THE PROPOSAL TO AMEND NUTRACEA’S 2005 EQUITY
INCENTIVE PLAN.
PROPOSAL
THREE
Amendment
of Articles of Incorporation
Our
board
of directors has determined that it is in the best interests of NutraCea and
our
shareholders to amend our articles of incorporation to increase the number
of
authorized shares of our common stock from 200,000,000 to 350,000,000 shares,
an
increase of 150,000,000 shares.
The
proposed form of amendment to our articles of incorporation to effect this
increase in the authorized number of shares of NutraCea common stock is attached
to this Proxy Statement as Annex E.
Below
is
a summary of the principal reasons why NutraCea's board of directors is
recommending that NutraCea shareholders approve the proposed amendment of
NutraCea's Articles of Incorporation.
Increase
in Authorized Common Shares
NutraCea
currently has 200,000,000 authorized shares of common stock and is now asking
our shareholders to approve the amendment of its articles of incorporation
to
increase the number of its authorized shares of common stock to 350,000,000
shares, an increase of 150,000,000 shares. As of April 23,
2007, 196,177,537 of the 200,000,000 authorized shares of common stock had
been issued or reserved for issuance as follows:
· |
135,625,849 shares
were issued and outstanding; and
|
· |
60,551,688 shares
were reserved for issuance upon exercise of outstanding stock options
and
warrants and for future grants under our 2005 Equity Incentive
Plan.
|
Therefore,
after deducting the outstanding and reserved shares of common stock described
above, there were approximately 3,822,463 million shares of NutraCea
common stock remaining unissued and reserved for issuance as of April 23, 2007.
If
the
proposed amendment of our articles of incorporation is approved, the additional
150,000,000 shares of common stock that would be authorized would be available
for issuance without further shareholder action, unless such action is otherwise
required by California law or any stock exchange on which our common stock
may
then be listed or quoted. Such shares could be issued directly by NutraCea,
or
could be reserved for issuance and then issued pursuant to the exercise of
warrants or options, or conversion of preferred stock, that could be granted
or
issued by NutraCea in the future. The additional authorized shares would be
part
of the existing class of our common stock and would not affect the terms of
the
outstanding NutraCea common stock or the rights of the holders of common stock.
Current shareholders will not have automatic rights to purchase any of the
additional authorized shares. Any future issuance of additional authorized
shares of our common stock will decrease the existing shareholders' percentage
equity ownership in NutraCea.
Our
board
of directors believes that an increase of 150,000,000 authorized common shares
will give NutraCea greater flexibility for possible future financings, joint
ventures and/or mergers and acquisitions of the businesses or assets of other
companies. Without such increase, it is possible that we would need to obtain
shareholder approval in connection with a transaction when it would not
otherwise be obligated to, thereby delaying, perhaps substantially, or even
causing the loss of, the transaction. Although we do not have any current plans,
proposals or arrangements, written or otherwise, to engage in any such
transaction, we continue to actively explore various business opportunities.
Recommendation
of the NutraCea Board of Directors
THE
BOARD RECOMMENDS A VOTE FOR THE PROPOSAL TO AMEND NUTRACEA’S ARTICLES OF
INCORPORATION
PROPOSAL
FOUR
Amendment
of Bylaws
Our
board
of directors has determined that it is in the best interests of NutraCea and
its
shareholders to amend NutraCea's Bylaws to eliminate cumulative voting in the
election of director if NutraCea becomes a listed corporation under California
corporation law.
On
April
18, 2007, our board of directors adopted, subject to shareholder approval,
an
amendment to our bylaws to eliminate cumulative voting at such time as we become
a listed corporation. The proposed form of amendment to NutraCea's Bylaws
attached to this Proxy Statement as Annex F.
Under
California General Corporations law, a corporation that is not a listed
corporation is required to allow for cumulative voting in the election of
directors. Under cumulative voting, each shareholder is entitled to as many
votes as is equal to the number of votes which such shareholder would be
entitled to cast for the election of directors with respect to such
shareholder’s shares of stock multiplied by the number of directors to be
elected. A shareholder may cast all such votes for a single candidate or may
distribute them among as many candidates as such shareholder chooses.
A
listed
corporation is defined under the California General Corporations law as a
corporation with outstanding shares listed on certain exchanges and markets
such
as the New York Stock Exchange, the American Stock Exchange, the NASDAQ Global
Market and the NASDAQ Global Select Market. However, a company is not a listed
corporation if the company’s shares are trading on the OTC Bulletin Board, which
is where NutraCea’s common stock currently trades.
The
Board
of Directors believes that each director should be elected only if he or she
receives the support of at least a plurality of shareholders and that each
director should represent the interests of, and be accountable to, all
shareholders, rather than the interests of a minority shareholder or a
particular shareholder constituency. With cumulative voting, however, it is
possible for shareholders holding a minority of our shares, whose interest
and
goals may not be consistent with those of a majority of shareholders, to obtain
representation on our board of directors. The Board believes that a director
who
represents a particular shareholder constituency may feel obligated to pursue
the agenda of that constituency to the detriment of the overall interests and
goals of all shareholders. In the Board’s opinion, this type of representation
increases the likelihood of factionalism and discord within the Board, thereby
impairing the efficient management of NutraCea. With cumulative voting
eliminated, a nominee can be elected only with relatively wide shareholder
support. The Board believes that a system of electing directors whereby only
those directors are elected who receive broad support from the shareholders
as a
whole will best ensure that the Board will act for the benefit of all
shareholders. Accordingly, the Board believes that it is in the best interests
of NutraCea and all of its shareholders to eliminate cumulative voting.
NutraCea
currently is not a listed corporation. Even if the shareholders approve the
amendment to our bylaws, cumulative voting will still apply to the election
of
director until we are a listed corporation. We do not know when or if NutraCea
will ever become a listed corporation.
Recommendation
of the NutraCea Board of Directors
THE
BOARD RECOMMENDS A VOTE FOR THE PROPOSAL TO AMEND NUTRACEA’S BYLAWS.
Compensation
Discussion and Analysis
General
Our
compensation arrangements with all but one person who served as our executive
officers for all or part of 2006 reflect the individual circumstances
surrounding the applicable executive officer’s hiring or appointment. For
example, Todd C. Crow and Ike E. Lynch, who became our executive officers at
the
time we acquired The RiceX Company, or RiceX, in October 2005, were parties
to
employment agreements with RiceX at the time of the acquisition. We assumed
these employment contracts in connection with the acquisition. Similarly, our
current compensation arrangements for Bradley D. Edson and Margie
D. Adelman are based upon objective formula contained in employment
agreements that we entered into with them in December 2004 and January 2005,
respectively. We did not have a compensation committee when we entered into
employment agreements with any of our named executive officers. Each of their
compensation arrangements were approved by our board of directors.
The
foregoing information is intended to provide context for the discussion that
follows regarding our existing compensation arrangements with those persons
who
served as our executive officers for all or part of 2006.
Principal
Components of Compensation of Our Executive Officers
The
principal components of the compensation we have historically paid to our
executive officers have consisted of:
· |
signing
bonuses, paid in cash;
|
· |
cash
incentive compensation under the terms of individual senior management
incentive compensation plans established for our executive officers;
and
|
· |
equity
compensation, generally in the form of grants of stock
options.
|
Allocation
of Compensation Among Principal Components
The
compensation committee of our board of directors has not yet established any
policies or guidelines with respect to the mix of base salary, bonus, cash
incentive compensation and equity awards to be paid or awarded to our executive
officers. In general, the compensation committee believes that a greater
percentage of the compensation of the most senior members of our management
should be performance-based. In 2007, the compensation committee of our board
of
directors anticipates adopting more formal and structured compensation policies
and programs. The compensation committee will endeavor to implement policies
designed to attract, retain and motivate individuals with the skills and
experience necessary for us to achieve our business objectives. These policies
will also serve to link pay with measurable performance, which, in turn, should
help to align the interests of our executive officers with our shareholders.
In
the past, our board of directors has not used industry benchmarks nor hired
compensation consultants when determining the compensation to be paid to
executive officers.
Base
Salary
Our
Chief Executive Officer
We
hired Bradley D. Edson as our president in December 2004, and he became our
chief executive officer in October 2005 concurrently with our acquisition of
RiceX. Mr. Edson’s employment agreement with us provides for an initial
base salary of $50,000 per year in year one, $150,000 in year two and $250,000
in year three, with base salary thereafter being subject to an annual increase
of 10% each year that Mr. Edson is employed with us. When structuring Mr.
Edson’s salary, our board considered the salary of our then chief executive
officer, the amount of equity compensation that Mr. Edson required, the value
that Mr. Edson could bring to NutraCea and our low cash position at the time.
Based upon these criteria, the Board determined that providing Mr. Edson with
base salary that started low and that grew substantially over time would allow
NutraCea to preserve its available cash while ultimately providing Mr. Edson
with the cash compensation appropriate for his position.
Our
Chief Financial Officer
We
hired
Todd C. Crow as our as our chief financial officer in October 2005 concurrent
with our acquisition of RiceX. Mr. Crow had served as the chief financial
officer of RiceX and we assumed his employment contract with RiceX. Our
employment agreement with Mr. Crow provides for an initial annual salary of
$150,000 with annual inflation adjustments. On January 1, 2006, his salary
was
increased to $155,600 to reflect the inflation adjustment.
Our
Chief Operating Officer
We
hired
Ike E. Lynch as our as our chief operating officer in October 2005 concurrent
with our acquisition of RiceX. Mr. Lynch had served as the chief operating
officer of RiceX and we assumed his employment contract with RiceX. Our
employment agreement with Mr. Lynch provides for an initial annual salary of
$150,000 with annual cost of living adjustments. On January 1, 2006, his salary
was increased to $155,600 to reflect the inflation adjustment. Mr. Lynch
resigned as our Chief Operating Officer on April 11, 2007.
Our
Secretary and Senior Vise President
We
hired
Margie D. Adelman as our senior vice president in January 2005. Our employment
agreement with Ms. Adelman provides for an initial annual salary of $150,000
and
requires that we re-evaluate her annual salary each year. On January 1, 2006,
her salary was $155,600, which reflected an increase in salary to reflect
inflation.
Our
Senior Vice President of Sales
We
hired
Kody K. Newland in February 2006 to serve as our senior vice president of sales.
Our employment agreement with Mr. Newland provides for an initial annual salary
of $150,000 with annual cost of living adjustments. When determining Mr.
Newland’s compensation, our board of directors considered the compensation that
our other executive officers were receiving and the experience of Mr. Newland.
Bonus
Compensation
We
have
not historically paid any automatic or guaranteed bonuses to our executive
officers. However, we have from time to time paid signing or retention bonuses
in connection with our initial hiring or appointment of an executive officer.
For example, in 2005, Ms. Adelman received a $25,000 signing bonus upon her
appointment as senior vice president. No other named executive officer has
received a bonus.
Compensation
under Individual Senior Management Incentive Compensation Plans
We
entered into an employee incentive compensation plan with Bradley D. Edson
when Mr. Edson executed his employment agreement with us. Under the plan, Mr.
Edson is entitled to an annual incentive bonus based upon objective performance
criteria of NutraCea during a fiscal year. The annual bonus is equal to one
percent of our gross sales over $25,000,000 in a year, but only if we report
a
positive EBITDA (earnings before interest, taxes, depreciation and amortization)
for the year, disregarding the effect of non-cash charges. The bonus amount
is
limited to a maximum of $750,000 in any calendar year. Mr. Edson has not earned
a bonus under the incentive compensation plan because we have not has gross
sales of $25,000,000 in any year. Given his low initial base salary, Mr. Edson
required that we provide him with incentive compensation plan as a condition
to
his accepting employment with us. Also, since low sales were a primary
impediment to our success at the time, our board determined that paying
compensation to Mr. Edson that was tied to our revenues would align NutraCea’s
and Mr. Edson’s goals.
Equity
Compensation
Our
board
of directors’ historical practice has been to grant equity-based awards to
attract, retain, motivate and reward our employees, particularly our executive
officers, and to encourage their ownership of an equity interest in us. Through
April 19, 2007, such grants have consisted primarily of stock options -
specifically non-qualified stock options, that is, options that do not qualify
as incentive stock options under Section 422 of the Internal Revenue Code
of 1986, as amended.
Historically,
our board has granted awards of stock options to our executive officers upon
their appointment as executive officers, with our obligation to grant the
options typically memorialized in the offer letter or employment agreement,
or
an addendum to an employment agreement, entered into with the applicable
executive officer. In 2004, 2005 and 2006, each of Mr. Edson, Ms. Adelman and
Mr. Newland received stock option grants under these circumstances. Mr. Edson’s
stock option was fully vested when granted. Ms. Adelman’s stock option vested as
to 25% of the shares when she was hired, vested as to 25% of the shares on
the
one year anniversary of her hire date and the remaining 50% of the shares will
vest only if we have gross sales over $25,000,000 in a year, but only if we
report a positive EBITDA (earnings before interest, taxes, depreciation and
amortization) for the year, disregarding the effect of non-cash charges. Mr.
Newland’s option was vested as to 20% of the underlying shares when granted and
the remaining unvested shares will vest over two years.
We
did
not grant new stock options to either of Mr. Crow or Mr. Lynch when they became
our executive officers. However, pursuant to the terms of the RiceX acquisition
we assumed all outstanding RiceX stock options, including the stock options
held
by Mr. Crow and Mr. Lynch.
Each
of
our executive officers are eligible to receive stock option grants under our
2005 Equity Incentive Plan, or the 2005 Plan. However, none of our executive
officers have been granted stock options other than in connection with their
initial employment with us. In 2006, our compensation committee determined
that
stock option grants to our executive officers, other than the initial employment
grant made to Mr. Newland, was not warranted based upon their current stock
option holdings.
All
equity-based awards have been reflected in our consolidated financial
statements, based upon the applicable accounting guidance. Previously, we
accounted for equity compensation paid to our employees under SFAS No. 123
and
compensation was recorded for option grants based on the excess of the estimated
fair value of the common stock on the vesting date over the exercise price.
Effective January 1, 2006, we adopted FAS 123R using the modified
prospective transition method. Under this method, stock-based compensation
expense is recognized using the fair-value based method for all awards granted
on or after the date of adoption of FAS 123R. FAS 123R requires us to estimate
and record an expense over the service period of the stock-based award. In
2006,
our compensation committee, conscious of the less favorable accounting treatment
for stock options resulting from adoption of FAS 123R, took a more deliberate
approach to the granting of awards of stock options.
We
currently intend that all cash compensation paid to our executive officers
will
be tax deductible for us. However, with respect to equity-based awards, while
any gain recognized by our executive officers and other employees from
non-qualified stock options generally should be deductible, subject to
limitations imposed under Section 162(m) of the Internal Revenue Code, to the
extent that in the future we grant incentive stock options, any gain recognized
by the optionee related to such options will not be deductible by us if there
is
no disqualifying disposition by the optionee.
We
may
not be able to deduct a portion of the equity compensation earned by our
executive officers. Section 162(m) of the Internal Revenue Code generally
prohibits us from deducting the compensation of an executive officer that
exceeds $1,000,000 in a year unless that compensation is based on the
satisfaction of objective performance goals. None of the stock options held
by
our executive officers qualify as performance based compensation under Section
162(m). Accordingly, if any of our executive officers recognizes income in
excess of $1,000,000, including amounts includible in income from the exercise
of stock options currently outstanding, this excess will not be tax deductible
by us. Our 2005 Equity Incentive Plan is structured to permit awards to qualify
as performance-based compensation and to maximize the tax deductibility of
such
awards. We may make future awards of stock options to our executive officers
under our 2005 Equity Incentive Plan. However, we reserve the discretion to
pay
compensation to our executive officers that may not be deductible.
We
do not
have any program, plan or practice that requires us to grant equity-based awards
on specified dates. Authority to make equity-based awards to executive officers
rests with our compensation committee, which considers the recommendations
of
our chief executive officer and other executive officers. If we become listed
on
a national securities exchange like NASDAQ in the future, we will be subject
to
NASDAQ listing standards that, in general, require shareholder approval of
equity-based plans.
Severance
and Change of Control Payments
Our
board
of directors believes that companies should provide reasonable severance
benefits to employees, recognizing that it may be difficult for them to find
comparable employment within a short period of time. Our board also believes
it
prudent that we should disentangle ourselves from employees whose employment
terminates as soon as practicable.
Our
employment agreement with Mr. Edson contains termination provisions that
are more complex than that in place for our other executive officers. The
compensation due Mr. Edson in the event of the termination of his
employment agreement varies depending on the nature of the termination and,
depending on the type and timing of the termination, provides for substantial
compensation payments to Mr. Edson. For additional information regarding
the termination and change in control provisions of Mr. Edson’s employment
agreement, see “Potential Payments Upon Termination or Change in Control.” We
believe that the termination and change in control provisions of
Mr. Edson’s employment agreement are comparable to those in effect for
chief executive officers of companies comparable to us, in terms of size,
revenue, profitability and/or nature of business.
Other
Benefits
We
believe establishing competitive benefit packages for our employees is an
important factor in attracting and retaining highly qualified personnel.
Executive officers are eligible to participate in all of our employee benefit
plans, such as medical, dental, vision, group life insurance and our 401(k)
plan, in each case on the same basis as other employees. We provide a matching
contribution under our 401(k) plan, but we do not offer retirement benefits.
Perquisites
Each
of
our executive officers receive similar perquisites. Under the terms of the
employment agreements with our executive officers, we are obligated to reimburse
each executive officer for all reasonable travel, entertainment and other
expenses incurred by them in connection with the performance of his duties
and
obligations under the agreement. The most significant perquisite that our
executive officers receive is an automobile allowance and other automobile
expenses, including insurance costs.
Board
Process
On
at
least an annual basis, the compensation committee of our board of directors
approves all compensation and awards to our chief executive officer, our
president and our chief financial officer. With respect to equity compensation
awarded to other employees, the compensation committee grants stock options,
generally based on the recommendation of our chief executive officer. In
addition, our compensation committee or board of directors may from time to
time
authorize our Chief Executive Officer to make stock option grants to
non-executive employees.
The
members of the Compensation Committee for the 2006 fiscal year were David S.
Bensol, James C. Lintzenich and Kenneth L. Shropshire. All members of the
Compensation Committee during 2006 were independent directors, and none of
them
were our employees or former employees. During 2006, none of our executive
officers served on the compensation committee (or equivalent), or the board
of
directors, of another entity whose executive officer(s) served on our
Compensation Committee or Board of Directors.
The
Compensation Committee has reviewed and discussed the Compensation Discussion
and Analysis with management. Based on its review and discussions with
management, the Compensation Committee recommended to the Board of Directors
that the Compensation Discussion and Analysis be included in NutraCea’s proxy
statement for the 2007 annual meeting of shareholders.
Respectfully
Submitted by the Compensation Committee
David
S.
Bensol
James
C. Lintzenich
Kenneth
L. Shropshire
Summary
Compensation Table
The
following table sets forth information regarding compensation earned in or
with
respect to our fiscal year 2006 by:
· |
each
person who served as our chief executive officer in
2006;
|
· |
each
person who served as our chief financial officer in 2006;
and
|
· |
our
three most highly compensated executive officers, other than our
chief
executive officer and our chief financial officer, who were serving
as
executive officers at the end of 2006 and, at that time, were our
only
other executive officers.
|
We
refer
to these officers collectively as our named executive officers.
Name
and Principal Position
|
|
Year
|
|
Salary
($)
|
|
Bonus
($)
|
|
Option
Awards
($)
(1)
|
|
All
Other Compensation
($)
|
|
Total
($)
|
|
Bradley
D. Edson, President and Chief Executive Officer
|
|
|
2006
|
|
|
159,723
|
|
|
—
|
|
|
—
|
|
|
22,307(2
|
)
|
|
183,030
|
|
Todd
C. Crow, Chief Financial Officer
|
|
|
2006
|
|
|
153,427
|
|
|
—
|
|
|
—
|
|
|
19,062(3
|
)
|
|
172,489
|
|
Ike
E. Lynch, Chief Operating Officer
|
|
|
2006
|
|
|
153,427
|
|
|
—
|
|
|
—
|
|
|
19,436(4
|
)
|
|
172,863
|
|
Margie
D. Adelman, Secretary and Senior Vice President
|
|
|
2006
|
|
|
154,504
|
|
|
—
|
|
|
—
|
|
|
16,324(5
|
)
|
|
170,828
|
|
Kody
K. Newland, Senior Vice President of Sales
|
|
|
2006
|
|
|
121,754
|
|
|
—
|
|
|
250,228
|
|
|
14,544(6
|
)
|
|
386,526
|
|
(1)
|
The
amounts in this column represent the dollar amount recognized for
financial statement reporting purposes with respect to the fiscal
year in
accordance with SFAS 123(R). The
assumptions used to calculate the value of option awards are set
forth in
Note 13 of the Notes to Consolidated Financial Statements included
in our
Annual Report on Form 10-K for 2006.
|
|
|
(2)
|
Consists
of an automobile allowance ($7,200), life insurance premium payments
($381), payment for unused personal time ($8,294) and a matching
401(k)
contribution ($6,432).
|
|
|
(3)
|
Consists
of an automobile allowance ($9,600), automobile insurance payments
($1,000), life insurance premium payments ($400), payment for unused
personal time ($3,362) and a matching 401(k) contribution
($4,700).
|
|
|
(4)
|
Consists
of an automobile allowance ($9,600), automobile insurance payments
($1,000), life insurance premium payments ($400) , payment for unused
personal time ($3,736) and a matching 401(k) contribution ($4,700).
On
April 11, 2007, Mr. Lynch resigned as our Chief Operating Officer
and Leo
Gingras was appointed our Chief Operating Officer.
|
|
|
(5)
|
Consists
of an automobile allowance ($7,200), life insurance premium payments
($381) , payment for unused personal time ($2,522) and a matching
401(k)
contribution ($6,221).
|
|
|
(6)
|
Consists
of an automobile allowance ($7,200), life insurance premium payments
($318) , payment for unused personal time ($3,606) and a matching
401(k)
contribution ($3,421).
|
2006
Grants Of Plan-Based Awards
Set
forth
in the table below is information regarding a stock option award granted to
a
named executive officer in 2006. This stock option grant represents all of
the
grants of awards to our named executive officers under any plan during or with
respect to 2006.
Name
|
|
Grant
Date
|
|
All
Other
Option Awards:
#
of Shares
Underlying
Options
|
|
Exercise Price
of
Options
($/Sh)
|
|
Close Price
on
Grant
Date
($/Sh)
|
|
Grant
Date
Fair
Value
of
Option
Awards
|
|
Kody
K. Newland
|
|
|
2/27/2006
|
|
|
500,000
|
|
$
|
1.00
|
|
$
|
1.02
|
|
$
|
505,512
|
|
The
fair
market value that is used to determine the exercise price for option grants
is
the closing price of NutraCea’s stock on the last market trading day prior to
the grant date as reported on the OTC Bulletin Board. The stock option granted
to Mr. Newland during 2006 expires on December 31, 2015, and the shares subject
to the option were vested as to 20% of the shares on the date of grant and
vest
as to 10% of the shares at the end of each successive calendar quarter in which
Mr. Newland remains a service provider for us.
We
adopted SFAS 123(R) on January 1, 2006. The grant date fair value of the
option awards is calculated using the Black-Scholes valuation model using the
following assumptions:
Assumption
|
|
Rate
|
|
Average
risk free interest rate
|
|
|
4.6
|
%
|
Average
expected term (years)
|
|
|
5.8
|
|
Average
expected volatility
|
|
|
214
|
%
|
Outstanding
Equity Awards As Of December 31, 2006
The
following table provides information as of December 31, 2006 regarding
unexercised stock options held by each of our named executive
officers.
|
|
Outstanding
Equity Awards at 12/31/06
|
|
Name
|
|
#
of Securities
Underlying
Unexercised
Options
(# Exerciseable)
|
|
#
of Securities
Underlying
Unexercised
Options
(# Unexerciseable)
|
|
Option
Exercise
Price
($/sh)
|
|
Option
Expiration
Date
|
|
Bradley
D. Edson
|
|
|
6,000,000
|
|
|
—
|
|
$
|
0.30
|
|
|
12/16/2014
|
|
Todd
C. Crow(1)
|
|
|
46,079
|
|
|
—
|
|
|
0.30
|
|
|
10/04/2008
|
|
|
|
|
38,399
|
|
|
—
|
|
|
0.30
|
|
|
10/04/2008
|
|
|
|
|
691,191
|
|
|
—
|
|
|
0.30
|
|
|
10/31/2009
|
|
|
|
|
76,799
|
|
|
—
|
|
|
0.30
|
|
|
2/22/2011
|
|
|
|
|
38,399
|
|
|
—
|
|
|
0.30
|
|
|
2/22/2011
|
|
|
|
|
38,399
|
|
|
—
|
|
|
0.30
|
|
|
1/28/2012
|
|
|
|
|
95,998
|
|
|
—
|
|
|
0.30
|
|
|
1/02/2012
|
|
|
|
|
425,662
|
|
|
112,016
|
|
|
0.30
|
|
|
3/31/2015
|
|
Ike
E. Lynch(2)
|
|
|
691,191
|
|
|
—
|
|
|
0.30
|
|
|
10/31/2009
|
|
|
|
|
30,719
|
|
|
—
|
|
|
0.30
|
|
|
9/09/2008
|
|
|
|
|
76,799
|
|
|
—
|
|
|
0.30
|
|
|
9/09/2008
|
|
|
|
|
95,998
|
|
|
—
|
|
|
0.30
|
|
|
1/02/2012
|
|
|
|
|
446,941
|
|
|
117,616
|
|
|
0.30
|
|
|
3/31/2015
|
|
Margie
D. Adelman(3)
|
|
|
1,000,000
|
|
|
—
|
|
|
0.30
|
|
|
1/24/2015
|
|
|
|
|
|
|
|
1,000,000
|
|
|
0.30
|
|
|
1/24/2015
|
|
Kody
K. Newland(4)
|
|
|
300,000
|
|
|
200,000
|
|
|
1.00
|
|
|
12/31/2015
|
|
(1)
|
For
the option expiring on March 31, 2015, one half of the shares subject
to
the option vested upon grant and 1/36th
of
the remaining shares vest monthly over three years
|
|
|
(2)
|
For
the option expiring on March 31, 2015, one half of the shares subject
to
the option vested upon grant and 1/36th
of
the remaining shares vest monthly over three years
|
|
|
(3)
|
The
unexerciseable option vests as to all 1,000,000 shares when NutraCea
achieves annual gross sales of at least $25,000,000 and a positive
EBITDA,
disregarding noncash charges, over the same period.
|
|
|
(4)
|
100,000
of the shares subject to the option vested upon grant and 50,000
shares
vest each calendar quarter
thereafter
|
2006
Option Exercises and Stock Vested
In
2006,
none of our named executive officers exercised any stock options or similar
awards we granted to them, nor did any stock or similar award granted by us
to
any of our named executive officers vest.
Pension
Benefits
None
of
our named executive officers are covered by a pension plan or other similar
benefit plan that provides for payments or other benefits at, following, or
in
connection with retirement.
Nonqualified
Deferred Compensation
None
of
our named executive officers are covered by a defined contribution or other
plan
that provides for the deferral of compensation on a basis that is not
tax-qualified.
Potential
Payments Upon Termination or Change in Control
We
have
entered into employment agreements with certain of our named executive officers
that require us to make payments upon termination or a change in control of
NutraCea. These arrangements are discussed below.
Bradley
D. Edson
The
compensation due Mr. Edson in the event of the termination of his
employment agreement with us varies depending on the nature of the termination.
Resignation
for Good Reason.
In the
event the agreement is terminated by reason of Mr. Edson’s resignation for “good
reason,” Mr. Edson is entitled to:
· |
100%
of his base salary through the end of the term of the agreement,
but no
less than the base salary paid to him in the previous 12 months,
to be
paid immediately following
termination;
|
· |
immediate
payment for accrued but unused vacation time;
and
|
· |
vesting
of all his unvested stock options.
|
“Good
Reason” is defined as (i) the assignment to Mr. Edson of duties that are
inconsistent with his position and nature of employment, (ii) the reduction
of
the duties which are inconsistent with his position and nature of employment,
(iii) a change in Mr. Edson’s title, (iv) a reduction in Mr. Edson’s
compensation and benefits, (v) a successor company not agreeing to assume the
agreement or (vi) a “Change of Control.”
Under
the
agreement, a “Change of Control” is defined as (i) a merger or consolidation
approved by our shareholders in which shares possessing more than 50% of the
total combined voting power of our outstanding stock are transferred to a person
or persons different from the persons holding those shares immediately before
such merger or consolidation, (ii) the transfer of more than 50% of the total
combined voting power of our outstanding stock to a person or persons different
from the persons holding those shares immediately before such transaction,
or
(iii) the sale, transfer or other disposition of all or substantially all of
our
assets in our complete liquidation or dissolution.
If
Mr.
Edson had resigned for good reason on December 31, 2006, Mr. Edson would
have been entitled to receive immediately an aggregate of $304,561, consisting
of $275,000 relating to his remaining salary under the agreement and $29,561
for
unused vacation time. All of Mr. Edson’s stock options were vested as of
December 31, 2006.
Permanent
Disability or Death.
In the
event the agreement is terminated by reason of Mr. Edson’s “permanent
disability” or death, Mr. Edson is entitled to:
· |
six
months of his base salary payable on regular periodic
installments;
|
· |
any
incentive compensation through the end of the fiscal year;
|
· |
immediate
payment for accrued but unused vacation time;
and
|
· |
vesting
of all his unvested options.
|
“Permanent
disability” is defined as Mr. Edson’s inability to carry on substantially all of
his normal duties and obligations under the agreement for a continuous period
of
one hundred eighty (180) days due to accident, illness or other disability.
If
Mr. Edson had been terminated on December 31, 2006, as a result of his
permanent disability or death, Mr. Edson would have received an aggregate
of $167,061, consisting of $137,500 for base salary that is payable on a
bi-weekly basis over a period of six (6) months from the date of termination
and
$29,561 for unused vacation time that is payable upon termination. Edson was
entitled to no incentive compensation for 2006. All of Mr. Edson’s stock options
were vested as of December 31, 2006.
Resignation
Without Good Reason and Termination for Cause.
In the
event the agreement is terminated by reason of Mr. Edson’s resignation without
“good reason” or for “cause,” Mr. Edson is entitled to:
· |
any
and all earned but unpaid base salary and any and all earned but
unpaid
incentive compensation as of the date of termination;
and
|
· |
immediate
payment for accrued but unused vacation
time.
|
“Cause”
is defined as the conviction of a felony, a crime involving moral turpitude
causing material harm to our standing and reputation or fraud against
us.
If
Mr.
Edson has resigned without good reason or was terminated for cause on December
31, 2006, Mr. Edson would have been entitled to receive an aggregate of $29,561
for unused vacation time, payable upon termination.
Termination
Without Cause.
In the
event the agreement is terminated by reason of Mr. Edson’s termination without
“cause,” Mr. Edson is entitled to:
· |
100%
of his base salary through the end of the term of the agreement,
but no
less than the base salary paid to him in the previous 12 months,
to be
paid immediately following
termination;
|
· |
all
incentive compensation through the end of the term of the
agreement;
|
· |
immediate
payment for accrued but unused vacation time;
and
|
· |
vesting
of all his unvested stock options.
|
If
Mr. Edson had been terminated on December 31, 2006, without cause,
Mr. Edson would have been entitled to receive immediately an aggregate of
$304,561, consisting of $275,000 relating to his remaining salary under the
agreement and $29,561 for unused vacation time. Assuming our financial results
in 2007 are the same as 2006, Mr. Edson would not be entitled to incentive
compensation. Accordingly, we did not include the effect of potential incentive
compensation payments that could be earned in 2007 if Mr. Edson were terminated
without cause. All of Mr. Edson’s stock options were vested as of December 31,
2006.
Margie
D. Adelman
The
compensation due Ms. Adelman in the event of the termination of her employment
agreement with us varies depending on the nature of the termination.
Termination
Without Cause.
In the
event the agreement is terminated by reason of Ms. Adelman’s termination without
“cause,” Ms. Adelman is entitled to:
· |
an
amount equal to 12 months of her then base salary, to be paid immediately
following termination;
|
· |
any
and all earned but unpaid base salary and benefits as of the date
of
termination; and
|
· |
payment
for accrued but unused vacation
time.
|
“Cause”
is defined as (i) a determination by the board of directors that Ms. Adelman
has
been grossly negligent or has engaged in material willful or gross misconduct
in
the performance of her duties and we have filed a civil lawsuit against her
for
the same claims, (ii) Ms. Adelman has taken or failed to take any actions such
that such action or failure constitutes legal cause for termination under
California law, (iii) Ms. Adelman has been convicted by a court of law of fraud,
moral turpitude, embezzlement, theft, or dishonesty or other criminal conduct,
(iv) Ms. Adelman having materially breached the terms of her employment
agreement and not cured the breach in 10 days after receipt of written notice
or
(v) Ms. Adelman having failed to meet written standards established by us for
performance of duties and not cured this failure within 10 days after receipt
of
written notice.
If
Ms.
Adelman had been terminated on December 31, 2006, without cause, Ms. Adelman
would have been entitled to receive immediately an aggregate of $167,353,
consisting of $155,400 twelve months of base salary and $11,953 for accrued
vacation time.
Termination
for Cause.
In the
event Ms. Adelman is terminated for “cause”, Ms. Adelman is entitled
to:
· |
any
and all earned but unpaid compensation as of the date of termination;
and
|
· |
immediate
payment for accrued but unused vacation
time.
|
If
Ms.
Adelman was terminated for cause on December 31, 2006, Ms. Adelman would have
been entitled to receive an aggregate of $11,953 for unused vacation time,
payable upon termination.
Disability.
In the
event the agreement is terminated by reason of Ms. Adelman’s “disability,” Ms.
Adelman is entitled to:
· |
twelve
months of his base salary payable in a lump
sum;
|
· |
continued
benefits for six months following termination;
and
|
· |
immediate
payment for accrued but unused vacation
time.
|
Under
the
agreement, Ms. Adelman is considered “disabled” if she is incapable of
substantially fulfilling her duties because of physical, mental or emotional
incapacity from injury, sickness or disease for a period of three (3) months
in
a twelve month period.
If
Ms.
Adelman had been terminated on December 31, 2006, as a result of her disability,
Ms. Adelman would have received aggregate amounts of $169,831, consisting of
$155,400 for twelve months of base salary, $11,953 for accrued vacation time
and
$2,478 for health insurance benefits. We estimate that it will cost us $2,478
in
premiums to maintain Ms. Adelman’s health insurance for a six month
period.
Todd
C. Crow
The
compensation due Mr. Crow in the event of the termination of his employment
agreement with us or a change of control varies depending on the nature of
the
termination.
Termination
Without Cause.
In the
event the agreement is terminated by reason of Mr. Crow’s termination without
“cause,” Mr. Crow is entitled to the greater of (i) Mr. Crow’s monthly base
salary times the number of months remaining on the terms of the agreement or
(ii) one year of Mr. Crow’s base salary.
“Cause”
is defined as (i) Mr. Crow’s willful and continued failure substantially to
perform his duties and obligations under the agreement after written demand
for
substantial performance has been delivered to him by us which sets forth with
reasonable specificity the deficiencies in Mr. Crow’s performance and giving Mr.
Crow at least thirty (30) days to correct such deficiencies, (ii) Mr. Crow
committing fraud or making intentionally material misrepresentations, (iii)
Mr.
Crow’s unauthorized disclosure or use of our trade secrets or confidential
information, (iv) Mr. Crow’s conviction of a felony, (v) theft or
conversion of our property by Mr. Crow, or (vi) Mr. Crow’s habitual misuse of
alcohol, illegal narcotics, or other intoxicant.
If
Mr.
Crow had been terminated on December 31, 2006, without cause, Mr. Crow would
have been entitled to receive immediately an aggregate of $284,900.
Termination
for Cause, voluntary resignation, death or disability.
In the
event Mr. Crow is terminated for “cause,” death, “disability” or if he
voluntarily resigns, Mr. Crow is entitled to:
· |
any
and all earned but unpaid compensation as of the date of termination;
and
|
· |
immediate
payment for accrued but unused vacation
time.
|
Under
the
agreement, Mr. Crow is considered “disabled” if he is incapable of substantially
fulfilling his duties because of physical, mental or emotional incapacity from
injury, sickness or disease, despite reasonable accommodation by NutraCea,
for a
period exceeding three (3) months.
If
Mr.
Crow was terminated for cause on December 31, 2006, Mr. Crow would have been
entitled to receive an aggregate of $2,002 for unused vacation time, payable
upon termination.
Termination
in Connection with a Change in Control.
In the
event that this agreement is terminated by reason of Mr. Crow’s termination as a
result of a “change in control” and Mr. Crow is not employed in the same
capacity or being paid the same base salary by the successor entity, Mr. Crow
is
entitled to:
· |
the
greater of (i) two years of base salary or (ii) the base salary remaining
to be paid through the term of the
agreement;
|
· |
continued
medical and dental benefits for two years after the change of control;
and
|
· |
payment
for accrued but unused vacation
time.
|
In
addition, Mr. Crow holds a stock option for 500,000 shares that vest as to
all
unexercised shares in the event of a change of control.
A
“change
in control” is defined in the agreement as (i) a merger or acquisition in which
we are not the surviving entity, except for (a) a transaction the principal
purpose of which is to change the state of our incorporation, or (b) a
transaction in which our shareholders immediately before such transaction hold,
immediately after such transaction, at least 50% of the voting power of the
surviving entity; (ii) a shareholder approved sale, transfer or other
disposition of all or substantially all of our assets; (iii) a transfer of
all
or substantially all of our assets pursuant to a partnership or joint venture
agreement or similar arrangement where our resulting interest is less than
fifty
percent (50%); (iv) any reverse merger in which we are the surviving entity
but
in which fifty percent (50%) or more of our outstanding voting stock is
transferred to holders different from those who held the stock immediately
before such merger; (v) a change in ownership of our stock through an action
or
series of transactions, such that any person is or becomes the beneficial owner,
directly or indirectly, of our stock representing fifty percent (50%) or more
of
the voting power of our outstanding stock; or (vi) a majority of the members
of
our board of directors are replaced during any twelve (12) month period by
directors whose appointment or election is not endorsed by a majority of the
members of our board of directors before the date of such appointment of
election.
If
Mr.
Crow had been terminated on December 31, 2006, by reason of Mr. Crow’s
termination as a result of a change in control and Mr. Crow was not employed
in
the same capacity or being paid the same base salary by the successor entity,
Mr. Crow would have been entitled to receive an aggregate of $586,878,
consisting of $310,800 for 2 years of base salary, $17,560 for the cost of
health and dental insurance premiums, $2,002 for accrued vacation benefits
and
$256,516 for the benefit of accelerating the vesting of Mr. Crow’s unvested
stock option. The benefit to Mr. Crow of the acceleration of his stock option
was calculated by multiplying the number of unvested shares underlying the
stock
option at December 31, 2006 (112,016) by the difference between the closing
price of our common stock on the trading day immediately before December 31,
2006 ($2.59) and the per share exercise price of the stock option
($0.30).
Ike
E. Lynch
The
compensation due Mr. Lynch in the event of the termination of his employment
agreement with us or a change of control varies depending on the nature of
the
termination.
Termination
Without Cause.
In the
event the agreement is terminated by reason of Mr. Lynch’s termination without
“cause,” Mr. Lynch is entitled to the greater of (i) Mr. Lynch’s monthly base
salary times the number of months remaining on the terms of the agreement and
(ii) one year of Mr. Lynch’s base salary.
“Cause”
is defined as (i) Mr. Lynch’s willful and continued failure substantially to
perform his duties and obligations under the agreement after written demand
for
substantial performance has been delivered to him by us which sets forth with
reasonable specificity the deficiencies in Mr. Lynch’s performance and giving
Mr. Lynch at least thirty (30) days to correct such deficiencies, (ii) Mr.
Lynch
committing fraud or making intentionally material misrepresentations, (iii)
Mr.
Lynch’s unauthorized disclosure or use of our trade secrets or confidential
information, (iv) Mr. Lynch’s conviction of a felony, (v) theft or
conversion of our property by Mr. Lynch, or (vi) Mr. Lynch’s habitual misuse of
alcohol, illegal narcotics, or other intoxicant.
If
Mr.
Lynch had been terminated on December 31, 2006, without cause, Mr. Lynch would
have been entitled to receive immediately an aggregate of $284,900.
Termination
for Cause, voluntary resignation, death or disability.
In the
event Mr. Lynch is terminated for “cause,” death, “disability” or if he
voluntarily resigns, Mr. Lynch is entitled to:
· |
any
and all earned but unpaid salary as of the date of termination;
and
|
· |
immediate
payment for accrued but unused vacation
time.
|
Under
the
agreement, Mr. Lynch is considered “disabled” if he is incapable of
substantially fulfilling his duties because of physical, mental or emotional
incapacity from injury, sickness or disease for an aggregate period of three
(3)
months in a twelve month period.
If
Mr.
Lynch was terminated for cause on December 31, 2006, Mr. Lynch would have been
entitled to receive an aggregate of $9,025 for unused vacation time, payable
upon termination.
Termination
in Connection with a Change in Control.
In the
event that this agreement is terminated by reason of Mr. Lynch’s termination as
a result of a “change in control” and Mr. Lynch is not employed in the same
capacity or being paid the same base salary by the successor entity, Mr. Lynch
is entitled to:
· |
continued
medical and dental benefits for two years after the change of control;
and
|
· |
payment
for accrued but unused vacation
time.
|
In
addition, Mr. Lynch holds a stock option for 500,000 shares that vests as to
all
unexercised shares in the event of a change of control.
A
“change
in control” is defined in the agreement as (i) a merger or acquisition in which
we are not the surviving entity, except for (a) a transaction the principal
purpose of which is to change the state of our incorporation, or (b) a
transaction in which our shareholders immediately before such transaction hold,
immediately after such transaction, at least 50% of the voting power of the
surviving entity; (ii) a shareholder approved sale, transfer or other
disposition of all or substantially all of our assets; (iii) a transfer of
all
or substantially all of our assets pursuant to a partnership or joint venture
agreement or similar arrangement where our resulting interest is less than
fifty
percent (50%); (iv) any reverse merger in which we are the surviving entity
but
in which fifty percent (50%) or more of our outstanding voting stock is
transferred to holders different from those who held the stock immediately
before such merger; (v) a change in ownership of our stock through an action
or
series of transactions, such that any person is or becomes the beneficial owner,
directly or indirectly, of our stock representing fifty percent (50%) or more
of
the voting power of our outstanding stock; or (vi) a majority of the members
of
our board of directors are replaced during any twelve (12) month period by
directors whose appointment or election is not endorsed by a majority of the
members of our board of directors before the date of such appointment of
election.
If
Mr.
Lynch had been terminated on December 31, 2006, by reason of Mr. Lynch’s
termination as a result of a change in control and Mr. Lynch was not employed
in
the same capacity or being paid the same base salary by the successor entity,
Mr. Lynch would have been entitled to receive an aggregate of $481,013,
consisting of a $180,000 payment, $22,648.00 for the cost of health and dental
insurance premiums, $9,025 for accrued vacation benefits and $269,340 for the
benefit of accelerating the vesting of Mr. Lynch’s unvested stock option. The
benefit to Mr. Lynch of the acceleration of his stock option was calculated
by
multiplying the number of unvested shares underlying the stock option at
December 31, 2006 (117,616) by the difference between the closing price of
our
common stock on the trading day immediately before December 31, 2006 ($2.59)
and
the per share exercise price of the stock option ($0.30).
Kody
K. Newland
Termination
Without Cause.
In the
event the agreement is terminated by reason of Mr. Newland’s termination without
“cause,” Mr. Newland is entitled to:
· |
an
amount equal to his base salary for the remainder of the term of
his
employment agreement, not to exceed 12
months;
|
· |
any
and all earned but unpaid base salary and benefits as of the date
of
termination; and
|
· |
payment
for accrued but unused vacation
time.
|
“Cause”
is defined as (i) a determination by the board of directors that Mr. Newland
has
been grossly negligent or has engaged in material willful or gross misconduct
in
the performance of her duties and we have filed a civil lawsuit against her
for
the same claims, (ii) Mr. Newland has taken or failed to take any actions such
that such action or failure constitutes legal cause for termination under
California law, (iii) Mr. Newland has been convicted by a court of law of fraud,
moral turpitude, embezzlement, theft, or dishonesty or other criminal conduct,
(iv) Mr. Newland having materially breached the terms of her employment
agreement and not cured the breach in 10 days after receipt of written notice
or
(v) Mr. Newland having failed to meet written standards established by us for
performance of duties and not cured this failure within 10 days after receipt
of
written notice.
If
Mr.
Newland had been terminated on December 31, 2006, without cause, Mr. Newland
would have been entitled to receive immediately an aggregate of $152,137,
consisting of $150,000 for twelve months of base salary and $2,137 for accrued
vacation time.
Termination
for Cause, death or disability.
In the
event Mr. Newland is terminated for “cause,” death or “disability,” Mr. Lynch is
entitled to:
· |
any
and all earned but unpaid salary as of the date of termination;
and
|
· |
immediate
payment for accrued but unused vacation
time.
|
Under
the
agreement, Mr. Newland is considered “disabled” if he is incapable of
substantially fulfilling his duties because of physical, mental or emotional
incapacity from injury, sickness or disease for an aggregate period of three
(3)
months in a twelve month period.
If
Mr.
Newland was terminated for cause on December 31, 2006, Mr. Newland would have
been entitled to receive an aggregate of $2,137 for unused vacation time,
payable upon termination.
Change
of Control Benefit.
In the
event of a “change of control”, Mr. Newland’s stock option to purchase 500,000
shares of our common stock will vest as to all unvested shares.
“Change
of control” is defined as (i) our merger or consolidation with any other
corporation which results in our voting stock outstanding immediately before
the
transaction failing to represent more than fifty percent (50%) of the total
voting power represented by the surviving entity immediately after the merger
or
consolidation or (ii) our sale or disposal of all or substantially all of our
assets.
If
a
change of control had occurred on December 31, 2006, 200,000 shares subject
to
Mr. Newland’s stock option would have immediately vested and Mr. Newland would
have received a benefit of $318,000. The benefit to Mr. Lynch of the
acceleration of his stock option was calculated by multiplying the number of
unvested shares underlying the stock option at December 31, 2006 (200,000)
by
the difference between the closing price of our common stock on the trading
day
immediately before December 31, 2006 ($2.59) and the per share exercise price
of
the stock option ($1.00).
Executive
Employment Agreements
Bradley
D. Edson
On
December 17, 2004, NutraCea entered into an employment agreement that expires
December 31, 2007 with its current President and Chief Executive Officer,
Bradley D. Edson, pursuant to which NutraCea is to pay Mr. Edson a base salary
of $50,000 in year one; a base salary of $150,000 in year two; and a base salary
of $250,000 in year three. The agreement also provides that Mr. Edson is
entitled to an annual incentive bonus based upon performance (“Edson Incentive
Bonus”) and to be provided a car allowance of $600 per month. The incentive
bonus is payable annually within 10 days of the completion of NutraCea’s annual
independent audit. The bonus is one percent of NutraCea’s “Gross Sales over $25,
000,000,” but only if NutraCea reports a positive EBITDA for the period. The
bonus amount is limited to a maximum of $750,000 in any calendar year. In
addition, Mr. Edson was issued warrants to purchase 6,000,000 shares of
NutraCea’s common stock at an exercise price of $0.30 per share. The warrants
are immediately exercisable and expire ten years from the date of
issuance.
For
a
description of the termination and change in control provisions of Mr. Edson’s
employment agreement, see “Potential Payments Upon Termination or Change in
Control.”
Margie
D. Adelman
On
January 25, 2005, NutraCea entered into a three year employment agreement with
Margie D. Adelman, NutraCea’s Senior Vice President and Secretary, pursuant to
which NutraCea is to pay Ms. Adelman a base salary of $150,000 per year. The
agreement also provides that Ms. Adelman is entitled to a one-time initial
bonus
of $25,000 and will be eligible for future incentive bonuses based solely on
the
discretion of NutraCea’s Chief Executive Officer or President and the approval
of NutraCea’s Compensation Committee. Ms. Adelman was issued a warrant to
purchase 1,000,000 shares of NutraCea’s common stock at an exercise price of
$0.30 per share, 500,000 shares of which vested upon signing and 500,000 shares
of which vested on January 25, 2006, subject to forfeiture under certain terms
and conditions. In addition, Ms Adelman was issued warrants to purchase
1,000,000 shares of NutraCea’s common stock at an exercise price of $0.30 that
will vest upon the achievement of NutraCea obtaining “Gross Sales over
$25,000,000” and NutraCea reporting a positive EBITDA for the period. All
warrants expire ten years from the date of issuance. On February 26, 2006,
the
agreement was modified to include a car allowance of $600 per month, a cost
of
living increase for the balance of the term of her agreement, and an additional
week of paid vacation per calendar year.
For
a
description of the termination and change in control provisions of Ms. Adelman’s
employment agreement, see “Potential Payments Upon Termination or Change in
Control.”
Todd
C. Crow
In
September 2005, we entered into a first amendment to employment agreement with
Todd C. Crow, pursuant to which we assumed the employment agreement between
Mr.
Crow and The RiceX Company. The employment agreement, as amended, provides
that
Mr. Crow will serve as Chief
Financial Officer of NutraCea and the RiceX Company. Mr. Crow’s employment
agreement, as amended, provides that Mr. Crow will receive an annual base
salary of $150,000, which salary will be reviewed annually and be adjusted
to
compensate for cost of living adjustments in the Sacramento metropolitan area.
The agreement terminates on October 4, 2008. The term will be automatically
extended for an additional one-year term unless either party delivers notice
of
election not to extend the employment at least 90 days prior to the
expiration of the initial term.
For
a
description of the termination and change in control provisions of Mr. Crow’s
employment agreement, see “Potential Payments Upon Termination or Change in
Control.”
Ike
E. Lynch
In
September 2005, we entered into a first amendment to employment agreement with
Ike E. Lynch, pursuant to which we assumed the employment agreement between
Mr.
Lynch and The RiceX Company. The employment agreement, as amended, provides
that
Mr. Lynch will serve as Chief Operating Officer of NutraCea, The RiceX
Company and RiceX Nutrients, Inc., a subsidiary of The RiceX Company. The
employment agreement, as amended, provides that Mr. Lynch will receive an
annual base salary of $150,000, which salary will be reviewed annually and
be
adjusted to compensate for cost of living adjustments in the Sacramento
metropolitan area. The agreement terminates on October 4, 2008. The term will
be
automatically extended for an additional one-year term unless either party
delivers notice of election not to extend the employment at least 90 days
prior to the expiration of the initial term.
For
a
description of the termination and change in control provisions of Mr. Lynch’s
employment agreement, see “Potential Payments Upon Termination or Change in
Control.”
Kody
K. Newland
On
February 27, 2006, NutraCea entered into a two year employment agreement with
Kody K. Newland, NutraCea’s Senior Vice President of Sales, pursuant to which
NutraCea is to pay Mr. Newland a base salary of $150,000 per year which will
be
reviewed annually and adjusted to compensate for cost of living adjustments
in
the Sacramento metropolitan area. The term of agreement may be extended by
mutual agreement of the parties on a month to month basis. The agreement also
provides that Mr. Newland is eligible for future incentive bonuses based solely
on the discretion of NutraCea’s Chief Executive Officer or President and the
approval of NutraCea’s Compensation Committee. Mr. Newland was issued an option
to purchase 500,000 shares of NutraCea’s common stock at an exercise price of
the greater of (i) one dollar ($1.00) per share; or (ii) the closing bid price
of NutraCea’s common stock on the date of the grant as reported on the
over-the-counter bulletin board. Such option is subject to the terms and
conditions of a stock option agreement between the parties. In addition, the
agreement includes a car allowance of $600 per month.
For
a
description of the termination and change in control provisions of Mr. Newland’s
employment agreement, see “Potential Payments Upon Termination or Change in
Control.”
The
following table set forth certain information regarding beneficial ownership
of
our common stock as of April 23, 2007, by (i) each person or entity who is
known
by us to own beneficially more than 5% of the outstanding shares of that class
or series of our stock, (ii) each of our directors, (iii) each of the Named
Executive Officers, and (iv) all directors and executive officers as a group.
The
table
is based on information provided to us or filed with the Securities and Exchange
Commission (“SEC”) by our directors, executive officers and principal
shareholders. Beneficial ownership is determined in accordance with the rules
of
the SEC, and includes voting and investment power with respect to shares. Shares
of common stock issuable upon exercise of options and warrants that are
currently exercisable or are exercisable within 60 days after April 23, 2007,
are deemed outstanding for purposes of computing the percentage ownership of
the
person holding such options or warrants, but are not deemed outstanding for
computing the percentage of any other shareholder. Unless otherwise indicated,
the address for each shareholder listed in the following table is c/o NutraCea,
5090 North 40th
Street,
Fourth Floor, Phoenix, Arizona 85018.
|
|
Shares
of Common Stock Beneficially Owned
|
|
Name
and Address of Beneficial Owner
|
|
Number
(1)
|
|
Percentage
(1)
|
|
Patricia
McPeak (2)
|
|
|
13,907,567
|
|
|
9.97
|
%
|
Bradley
D. Edson (3)
|
|
|
6,176,000
|
|
|
4.36
|
%
|
James
C. Lintzenich (4)
|
|
|
2,918,019
|
|
|
2.13
|
%
|
Ike
E. Lynch (5)
|
|
|
1,765,926
|
|
|
1.22
|
%
|
Todd
C. Crow (6)
|
|
|
1,505,432
|
|
|
1.10
|
%
|
Steven
W. Saunders (7)
|
|
|
1,305,994
|
|
|
*
|
|
Margie
D. Adelman (8)
|
|
|
1,071,207
|
|
|
*
|
|
Kody
K. Newland (9)
|
|
|
360,000
|
|
|
*
|
|
Edward
L. McMillan (10)
|
|
|
206,337
|
|
|
*
|
|
David
S. Bensol (11)
|
|
|
75,000
|
|
|
*
|
|
Kenneth
L. Shropshire (12)
|
|
|
35,000
|
|
|
*
|
|
Wesley
K. Clark (13)
|
|
|
5,834
|
|
|
*
|
|
All
directors and executive officers as a group (11 persons)
(14)
|
|
|
27,588,334
|
|
|
18.30
|
%
|
(1)
|
Applicable
percentage of ownership is based on 135,625,849 shares of our common
stock
outstanding as of April 23, 2007, together with applicable options
and
warrants for such shareholder exercisable within 60 days of April
23,
2007.
|
|
|
(2)
|
Includes
3,903,655 shares issuable upon exercise of options held by reporting
person. Also includes 153,598 shares held by a trust controlled by
the
reporting person.
|
|
|
(3)
|
Includes
6,000,000 shares issuable upon exercise of options.
|
|
|
(4)
|
Includes
1,521,608 shares issuable upon exercise of warrants and 1,396,411
outstanding shares held by the James C. Lintzenich Revocable Trust.
|
|
|
(5)
|
Includes
1,388,694 shares issuable upon exercise of options held by the reporting
person and 90,620 held by the reporting person’s spouse. The reporting
person disclaims beneficial ownership with regard to all shares owned
by
his spouse. Mr. Lynch resigned as Chief Operating Officer on April
11,
2007.
|
|
|
(6)
|
Includes
1,495,732 shares issuable upon exercise of options and
warrants.
|
(7)
|
Includes
542,192 shares issuable upon exercise of options and
warrants.
|
|
|
(8)
|
Includes
68,707 shares and an additional 2,500 shares issuable upon exercise
of
options held by Adelman Global of which the filing person is the
owner.
Also includes 1,000,000 shares issuable upon exercise of options
held by
the reporting person.
|
|
|
(9)
|
Includes
350,000 shares issuable upon exercise of options.
|
|
|
(10)
|
Includes
111,789 shares issuable upon exercise of options held by the reporting
person. Also includes 76,799 shares issuable upon exercise of warrants
jointly held by the reporting person and his spouse.
|
|
|
(11)
|
Includes
35,000 shares issuable upon exercise of options.
|
|
|
(12)
|
Includes
35,000 shares issuable upon exercise of options.
|
|
|
(13)
|
Includes
5,834 shares issuable upon exercise of options.
|
|
|
(14)
|
Includes
an aggregate of 15,102,062 shares issuable upon exercise of options
and
warrants.
|
Equity
Compensation Plan Information
The
following table sets forth, as of December 31, 2006, information with
respect to NutraCea’s 2003 Stock Plan and 2005 Equity Incentive Plan, and with
respect to certain other options and warrants, as follows:
Plan Category
|
|
Number of securities
to be issued
upon exercise of
outstanding options,
warrants and rights
(a)
|
|
Weighted average
exercise price of
outstanding options,
warrants and rights
(b)
|
|
Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column a)
(c)
|
|
Equity
compensation plans approved by shareholders
|
|
|
—
|
|
|
—
|
|
|
10,000,000
|
(1)
|
Equity
compensation plans not approved by shareholders
|
|
|
42,488,556
|
|
$
|
0.76
|
|
|
33,792
|
(2)
|
Total
|
|
|
42,488,556
|
|
$
|
0.76
|
|
|
10,033,792
|
|
(1)
Represents
shares reserved for issuance under the 2005 Equity Incentive
Plan.
(2)
Represents
shares reserved for future issuance under NutraCea’s 2003 Stock Compensation
Plan.
Our
board
of directors adopted our 2003 Stock Compensation Plan, or the 2003 Plan, on
October, 2003. Under the terms of the 2003 Plan, NutraCea may grant options
to
purchase common stock and shares of common stock to officers, directors,
employees or consultants providing services to NutraCea on such terms as are
determined by the board of directors. A total of 10,000,000 shares of our common
stock are reserved for issuance under the 2003 Plan. As of December 31, 2006
a
total of 9,996,207 shares were issued under the 2003 Plan, no shares underlie
outstanding stock option granted pursuant to the 2003 Plan and 3,793 shares
were
available for future grants under the Plan. Our board of directors administers
the 2003 Plan and determines vesting schedules on plan awards. The 2003 Plan
has
a term of 10 years and stock options granted under the plan may not have terms
in excess of 10 years. The Board may accelerate unvested options if NutraCea
sells substantially all of its assets or is a party to a merger or consolidation
in which NutraCea is not the surviving corporation. All options will terminate
in their entirety to the extent not exercised on or prior to the date specified
in the written notice unless an agreement governing any change of control
provides otherwise.
A
description of the 2005 Equity Incentive Plan is set forth above under Proposal
2.
As
of
December 31, 2006, options and warrants to purchase a total of 42,488,556
shares of NutraCea common stock were outstanding. None of these options and
warrants were issued pursuant to plans or arrangements approved by NutraCea’s
shareholders. The per share exercise prices of these options and warrants vary
from $0.01 to $10.00.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
During
2006, we believe that there has not been any transaction or series of similar
transactions to which we were or are to be a party in which the amount involved
exceeds $120,000 and in which any director, executive officer or holder of
more
than 5% of any class of our capital stock, or members of any such person’s
immediate family, had or will have a direct or indirect material interest,
other
than compensation described in “Executive Compensation,” and as set forth below.
Related
Party Transactions
In
April
2005, a direct response marketing company agreed to pay Patricia McPeak, our
former Chief Executive Officer and one of our directors, a royalty per unit
of
our products sold through infomercials that demonstrate certain of our products.
Pursuant to this agreement, Ms. McPeak should have earned approximately $270,000
in each of 2005 and 2006 from this direct marketing company. These payments
are
not the obligations of NutraCea.
In
May
2006, we sold approximately 17,560 shares of our Series C preferred stock at
a
price of $1,000.00 per share, and warrants to purchase an aggregate of
10,329,412 shares of our common stock with an exercise price of $1.35 per share,
to a small number of sophisticated investors in a private placement
transactions. Our Series C preferred stock can be converted to shares of our
common stock at a conversion rate of approximately 1176 shares of common stock
for each share of Series C preferred Stock. Gross proceeds from the offering
were approximately $17.56 million. The investors included The Pinnacle Fund,
L.P., funds related to WS Management, Funds related to Enable Partners, Gryphon
Master Fund, Sherleigh Associates Profit Sharing Plan, Bushido Capital Master
Fund, Funds related to SRB Greenway Capital, Westpark Capital, Iroquois Master
Fund and Funds related to Xerion Partners Equity, which purchased 3,000, 2,000,
1,150, 1,000, 1,000, 1,000, 1,000, 1,000, 1,000 and 500 shares of Series C
preferred stock, respectively. At the time of this private placement, each
of
the aforementioned investors beneficially held greater than either 5% of our
outstanding common stock or 5% of our outstanding preferred stock.
Review,
Approval or Ratification of Transactions with Related Parties
It
is our
unwritten policy, which policy is not otherwise evidenced, for any related
party
transaction that involves more than a de minimis obligation, expense or payment,
to obtain approval by our board of directors prior to our entering into any
such
transaction. In conformity with our various policies on related party
transactions, each of the above transactions discussed in this “Certain
Relationships and Related Party Transactions” section has been reviewed and
approved by our board of directors. In addition, the charter for our Audit
Committee, which was approved by our board of directors on April 18, 2007,
requires that all related party transactions be approved by our Audit
Committee.
Change
in Independent Auditor
As
previously reported in Nutracea’s Current Report on Form 8-K filed with the
Securities and Exchange Commission on December 15, 2006, on December 11, 2006
NutraCea dismissed its independent auditor, Malone & Bailey, PC (“Malone”)
and appointed Perry-Smith LLP (“Perry-Smith”) as its new independent auditor.
These actions were approved by our Board of Directors upon the recommendation
of
our Audit Committee.
Malone’s
reports on NutraCea’s financial statements for the two fiscal years ended
December 31, 2005 and 2004, did not contain an adverse opinion or disclaimer
of
opinion and were not qualified or modified as to uncertainty, audit scope or
accounting principles. During the two fiscal years ended December 31, 2005
and
2004, and through December 11, 2006, there were no disagreements between
NutraCea and Malone on any manner of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of Malone, would have caused
it to make reference to the subject matter of the disagreements in connection
with its report on NutraCea’s financial statements for such years. None of the
reportable events described under Item 304(a)(1)(v) of Regulation S-K occurred
within the fiscal years of NutraCea ended December 31, 2005 and 2004, or within
the interim period through December 11, 2006. Malone & Bailey’s letter to
the Securities and Exchange Commission stating its agreement with the statements
in this paragraph is filed as Exhibit 16 to NutraCea’s Current Report on
Form 8-K filed with the Securities and Exchange Commission on December 15,
2006.
During
the fiscal years ended December 31, 2005 and 2004, and through December 10,
2006, neither NutraCea nor anyone acting on its behalf consulted with
Perry-Smith regarding any matters or events set forth in Item 304(a)(2)(i)
and
(ii) of Regulation S-B.
The
information contained in the following report shall not be deemed to be
“soliciting material” or to be filed with the Securities and Exchange
Commission, nor shall such information be incorporation by reference into any
future filing under the Securities Act of 1933 or the Securities Exchange Act
of
1934, except to the extent that NutraCea specifically incorporates it by
reference into such filing.
The
following is the Audit Committee’s report submitted to the Board of Directors
for the fiscal year ended December 31, 2006.
The
Audit
Committee of the Board of Directors has:
· |
reviewed
and discussed with NutraCea’s management the audited consolidated
financial statements for the fiscal year ended December 31,
2006;
|
· |
discussed
with Perry-Smith LLP, NutraCea’s independent auditors, the matters
required to be discussed by Statement on Auditing Standards
No. 61;
|
· |
received
the written disclosures and the letter from Perry-Smith LLP required
by
Independence Standards Board Standard No. 1 and has discussed with
Perry-Smith LLP its independence;
and
|
· |
considered
whether the provision of non-audit services as noted below is compatible
with maintaining the independence of Perry-Smith, LLP, and has determined
that such provision of non-audit services is
compatible.
|
Based
on
the foregoing review and discussion, the Audit Committee recommended to the
Board of Directors that the audited financial statements be included in
NutraCea’s Annual Report on Form 10-K for the fiscal year ended December 31,
2006.
|
|
James
C. Lintzenich, chairman
David
S. Bensol
Edward
L. McMillan
|
Independent
Public Accountants
NutraCea’s
independent public accountants for the last completed fiscal year ended
December 31, 2006, were Perry-Smith LLP. The Board anticipates that
representatives of Perry-Smith will be present at the Annual Meeting, will
have
an opportunity to make a statement if they desire to do so, and will be expected
to be available to respond to appropriate questions. The Audit Committee has
not
yet selected its principle independent registered public accounting firm to
perform the audit of NutraCea’s financial statements for 2007. The Audit
Committee anticipates the selection will occur at its next scheduled meeting
on
June 19, 2007.
The
following table presents fees for professional services rendered by Perry-Smith
to us for the audit of our annual financial statements for the year ended
December 31, 2006, and fees billed for audit-related services, tax services
and
all other services rendered to us by Perry-Smith for 2006. The table also
presents fees for professional services rendered by Malone for the audit of
our
annual financial statements for fiscal 2005 and fees billed for audit-related
services, tax services and all other services rendered to NutraCea by Malone
for
the portion of 2006 during which such firm served as NutraCea’s independent
auditors.
Fees
|
|
2006
|
|
2005
|
|
Audit
Fees
|
|
$
|
147,000(1
|
)
|
$
|
56,000(1
|
)
|
Audit-related
Fees
|
|
|
40,000
|
|
|
—
|
|
Tax
Fees
|
|
$
|
18,000
|
|
$
|
10,000
|
|
All
other fees
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
205,000
|
|
$
|
66,000
|
|
(1)
|
Includes
$88,000 billed by Perry-Smith and $59,000 billed by Malone in 2006.
Includes $12,000 billed by Perry-Smith and $44,000 billed by Malone
in
2005. All other amounts in 2006 and 2005 were billed by Malone.
|
Audit
fees. Audit
fees relate to services related to the audit of NutraCea’s financial statements
and review of financial statements included in NutraCea’s quarterly reports on
Form 10-Q, including review of registration statements filed with the SEC.
Audit-related
fees. This
category includes fees for assurance and related services that are reasonably
related to the performance of the audit or review of NutraCea’s financial
statements and are not included under “Audit Fees,” and include fees for
consultations concerning financial accounting and reporting matters, and
Sarbanes-Oxley Act, Section 404 advisory services.
Tax
fees. Tax
fees
include fees for services rendered in connection with preparation of federal,
state and foreign tax returns and other filings and tax consultation services.
All
other fees. There
were no other fees in 2006 and 2005.
NutraCea
did not have a separate Audit Committee during fiscal year 2005. All of the
functions of the Audit Committee were performed by the Board of Directors as
a
whole, including the review and authorization of all non-audit fees incurred
by
NutraCea. All of the non-audit fees incurred by NutraCea were authorized by
the
Board of Directors
Under
our
current pre-approval policies with respect to our independent accountants,
the
Audit Committee pre-approves all audit and non-audit services provided by our
independent accountants prior to the engagement of the independent accountants
for such services. All fees reported under the headings Audit fees,
Audit-related fees, Tax fees and All other fees above for 2006 were approved
by
the Audit Committee before the respective services were rendered, which
concluded that the provision of such services was compatible with the
maintenance of the independence of the firm providing those services in the
conduct of its auditing functions.
SECTION 16(a) BENEFICIAL
OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of
the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires
NutraCea’s directors, executive officers and holders of more than 10% of a
registered class of NutraCea’s equity securities to file with the Securities and
Exchange Commission, (“SEC”) initial reports of ownership and reports of changes
in ownership of NutraCea’s common stock and other equity securities. Directors,
executive officers and greater than 10% shareholders are required by SEC
regulation to furnish NutraCea with copies of all
Section 16(a) reports they file. Based solely on the review of the
copies of such forms furnished to NutraCea, NutraCea believes that all reporting
requirements under Section 16(a) for the fiscal year ended
December 31, 2006 were met in a timely manner by the directors, executive
officers and greater than 10% beneficial owners.
NutraCea’s
management knows of no other business to be brought before the 2007 Annual
Meeting of Shareholders. If, however, any other business should properly come
before the annual meeting, the persons named in the accompanying proxy will
vote
proxies as in their discretion, as they may deem appropriate, unless they are
directed by a proxy to do otherwise.
ANNUAL
REPORT ON FORM 10-K
Shareholders
may obtain a copy of the Annual Report on Form 10-K for the fiscal year ended
December 31, 2006, without charge, by writing to Todd C. Crow, NutraCea’s Chief
Financial Officer, at NutraCea’s principal executive offices at 5090 North
40th
Street,
Fourth Floor, Phoenix, Arizona 85018.
|
|
|
|
By
Order of the Board of Directors |
|
|
/s/ TODD
C.
CROW |
|
Todd
C. Crow
Chief
Financial Officer
|
Phoenix,
Arizona
May
21, 2007
|
|
|
5090
NORTH 40th
STREET, FOURTH FLOOR
PHOENIX,
ARIZONA 85018
THIS
PROXY IS SOLICITED ON BEHALF OF
THE
COMPANY'S BOARD OF DIRECTORS
The
undersigned holder of Common Stock of NutraCea, a California corporation (the
"Company"), hereby appoints Bradley D. Edson and Todd C. Crow, and each of
them,
as proxies for the undersigned, each with full power of substitution, for and
in
the name of the undersigned to act for the undersigned and to vote, as
designated on the reverse side of this proxy card, all of the shares of stock
of
the Company that the undersigned may be entitled to vote at the 2007 Annual
Meeting of Shareholders of the Company, to be held at The Ritz Carlton, 2401
East Camelback Road, Phoenix, Arizona 85016, on Tuesday, June 19, 2007, from
9:00 A.M. to 11:00 A.M., local time, and at any adjournments or
postponements thereof, and in their discretion upon such other business as
may
properly come before the Annual Meeting or any adjournments or postponements
thereof.
|
|
|
|
|
(change
of address/comments)
__________________________________
__________________________________
__________________________________
__________________________________
__________________________________
|
|
|
|
|
|
(If
you have written in the above
spaces
please mark the
corresponding
box on the reverse
side
of this card.)
(continued
and to be signed on reverse
side)
|
PLEASE
DATE, SIGN AND MAIL YOUR
PROXY
CARD BACK AS SOON AS POSSIBLE!
ANNUAL
MEETING OF SHAREHOLDERS
NUTRACEA
June
19, 2007
Please
Detach and Mail in the Envelope Provided
This
proxy is being solicited on behalf of the Board of Directors of
NutraCea.
[X]
Please mark your votes as in this example
The
Board
of Directors recommends that you vote “For” the election of all nominees and
“For” each of the other Proposals listed below.
1. |
|
Election of
Directors:
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
WITHHELD |
|
|
|
|
|
|
|
|
|
|
|
|
|
Bradley D. Edson |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
|
|
David S. Bensol |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
|
|
Wesley K. Clark |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
|
|
James C. Lintzenich |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
|
|
Edward L. McMillan |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
|
|
Steven W. Saunders |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
|
|
Kenneth L. Shropshire |
|
[_] |
|
[_] |
|
[_] |
|
[_] |
2. |
|
Approval of Amendment
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
WITHHELD |
|
|
NutraCea 2005 Equity
Incentive Plan
|
|
[_] |
|
[_] |
|
[_] |
|
[_] |
3. |
|
Approval of Amendment
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
WITHHELD |
|
|
to NutraCea’s Articles of
Incorporation
|
|
[_] |
|
[_] |
|
[_] |
|
[_] |
4. |
|
Approval of Amendment
|
|
FOR |
|
AGAINST |
|
ABSTAIN |
|
WITHHELD |
|
|
to NutraCea’s Bylaw
|
|
[_] |
|
[_] |
|
[_] |
|
[_] |
5. |
|
In their discretion
on any other
matter that may properly come before the meeting or any adjournment
thereof. |
Please
check this box if you plan to attend the Annual Meeting. [_]
Change
of
Address / Comments [_]
Signature(s)
______________________________ Date __________________
NOTE: |
Please
sign exactly as name appears above. Joint owners should
each
|
sign.
Fiduciaries should add their full title to their signature.
Corporations
should sign in full corporate name by an authorized
officer.
Partnerships should sign in partnership name by an
authorized
person.
DETACH
& RETURN PROXY CARD, RETAIN ADMISSION CARD
ADMISSION
CARD
ANNUAL
MEETING OF SHAREHOLDERS
June
19, 2007
9:00
A.M. (Local Time)
The
Ritz Carlton
2401
East Camelback Road
Phoenix,
Arizona
Presentation
of this card is required
for
admission to the Annual Meeting
PLEASE
PRESENT THIS CARD TO THE COMPANY’S REPRESENTATIVE
AT
THE
ENTRANCE TO THE ANNUAL MEETING
NUTRACEA
Name:
_______________________
Address:
_____________________
Non-Transferable
Annex
A
CHARTER
OF THE AUDIT COMMITTEE
OF
THE
BOARD
OF DIRECTORS
OF
NUTRACEA
A. PURPOSE
AND COMPOSITION
This
Charter specifies the scope and responsibilities of the Audit Committee of
the
Board of Directors (“Board”) of NutraCea (“Company”) and the manner in which
those responsibilities shall be performed, including its structure, processes
and membership requirements. The primary purpose of the Audit Committee is
to
oversee the accounting and financial reporting processes of the Company.
The
Audit
Committee shall comprise three or more directors selected by the Board, each
of
whom shall satisfy the independence and experience requirements of the
Securities and Exchange Commission (“SEC”) and any market or exchange on which
the Company’s common stock is then listed or quoted for trading (“Trading
Market”); provided that one director who does not meet the independence criteria
of the Trading Market, but is not a current employee or officer, or an immediate
family member of an employee or officer, may be appointed to the Audit
Committee, subject to the approval of the Board pursuant to any exception
provided by the Trading Market. In addition, the Audit Committee shall not
include any member who:
· |
Accepts
any consulting, advisory, or other compensatory fee, directly or
indirectly, from the Company, other than in his or her capacity as
a
member of the Audit Committee, the Board, or any other committee
of the
Board; or
|
· |
Is
an affiliate of the Company or any subsidiary of the Company, other
than a
director who meets the independence requirements of the SEC and the
Trading Market.
|
Each
member of the Audit Committee must be able to read and understand fundamental
financial statements, including a balance sheet, income statement and cash
flow
statement. In addition, at least one member shall be an audit committee
financial expert as determined by the Board in accordance with the rules of
the
SEC.
The
members of the Audit Committee shall be appointed by the Board and shall serve
until their successors are duly elected and qualified or their earlier
resignation or removal. Any member of the Audit Committee may be replaced by
the
Board. Unless a chairman is elected by the Board, the members of the Committee
may designate a chairman by majority vote of the full Committee
membership.
B. FUNCTIONS
The
functions of the Audit Committee are to:
1. |
Review
the adequacy of the outside and inside auditing and control systems
and
procedures.
|
2. |
Review
the Company's financial and accounting policies and disclosures and
approve changes therein.
|
3. |
Review
the year-end financial statements to be included in the Annual Report
on
Form 10-K with management and the external
auditors.
|
4. |
Discuss
the effects of significant events, transactions and changes in accounting
estimates, which were considered by the external auditors in performing
the quarterly reviews and have affected the quality of NutraCea's
financial reporting.
|
5. |
Review
the financial reports published.
|
C. DUTIES
1. |
As
related to oversight of the Company's independent
auditors:
|
a. Be
directly and solely responsible for the appointment, compensation, retention
and
oversight of any independent auditor (including resolution of disagreements
between management and the independent auditor regarding financial reporting)
engaged by the Company for the purpose of preparing or issuing an audit report
or related work, and each such auditor reporting directly to the Audit
Committee.
b. Evaluate
annually the qualifications, performance and independence of the independent
auditor and report to the Board on its conclusions, together with any
recommendations for additional action.
c. Approve
as necessary the termination of the engagement of the independent
auditor.
d. Approve
the key engagement partners of the external auditors.
e. Approve
the overall scope of the external auditors' audit.
f. At
least
annually, review the results of the audit with emphasis on the
following:
|
-
|
The
external auditors' opinion of the Company's internal
controls.
|
|
-
|
The
external auditors' opinion as to the qualifications of financial
and
control personnel.
|
g. Discuss
the external auditors' judgments about the quality, not just acceptability,
of
the application of accounting principles used and significant judgments
affecting the financial statements.
h. Periodically
review and discuss with the independent auditor (i) the matters required to
be
discussed by Statement on Auditing Standards No 61, as amended, and (ii) any
formal written statements received from the independent auditor consistent
with
and in satisfaction of Independence Standards Board Standard No. 1, as amended,
including without limitation, descriptions of (x) all relationships between
the
auditor and the Company, (y) any disclosed relationships or services that may
impact the independent auditor’s objectivity and independence and (z) whether
any of the Company’s senior finance personnel were recently employed by the
independent auditor.
i. Regularly
review with the independent auditor any significant difficulties encountered
during the course of the audit, any restrictions on the scope of work or access
to required information and any significant disagreement among management and
the independent auditor in connection with the preparation of the financial
statements. Review with the independent auditor any accounting adjustments
that
were noted or proposed by the auditor but that were “passed” (as immaterial or
otherwise), any “management” or “internal control” letter or schedule of
unadjusted differences issued, or proposed to be issued, by the auditor to
the
Company, or any other material written communication provided by the auditor
to
the Company’s management.
j. Approve
in advance the engagement of the independent auditor for all audit services
and
non-audit services, based on independence, qualifications and, if applicable,
performance, and approve the fees and other terms of any such
engagement.
k. Meet
periodically with the external auditors without management present.
l. Review
with the independent auditor the critical accounting policies and practices
used
by the Company.
2. |
Review
of Financial Reporting, Policies and
Processes
|
a. Review
and discuss with management and the independent auditor the Company’s annual
audited financial statements and any certification, report, opinion or review
rendered by the independent auditor.
b. Review
and discuss with management and the independent auditor the Company’s quarterly
financial statements.
c. Review
and discuss with management and the independent auditor the Company’s disclosure
under “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” appearing in the Company’s periodic reports.
d. Review
with management and the independent auditor any significant judgments made
in
management’s preparation of the financial statements and the view of each as to
the appropriateness of the judgments.
e. To
the
extent that it deems appropriate, review with management its evaluation of
the
company’s procedures and controls designed to assure that information required
to be disclosed in its periodic public reports is recorded, processed,
summarized and reported in such reports within tithe time periods specified
by
the SEC for the filing of such reports (“Disclosure Controls”), and consider
whether any changes are appropriate in light of management’s evaluation of the
effectiveness of such Disclosure Controls.
f. Review
any special audit steps adopted in light of material control deficiencies.
Review with the independent auditor and management the extent to which changes
or improvements in financial or accounting practices, as approved by the Audit
Committee, have been implemented.
3. |
As
related to the internal auditors (if
applicable):
|
a. Approve
overall scope of the internal audit program.
b. Review
the internal auditors' annual and interim reports to the Committee.
c. Review
internal controls.
d. Meet
periodically with the internal auditor without management present.
4. |
Duties
relating to Risk Management, Related Party Transactions, Legal Compliance
and Ethics
|
a. Review
with the chief executive and chief financial officer of the Company any report
on significant deficiencies in the design or operation of the Internal Controls
that could adversely affect the Company’s ability to record, process, summarize
or report financial data, any material weaknesses in Internal Controls
identified to the auditors, and any fraud, whether or not material, that
involves management or other employees who have a significant role in the
Company’s Internal Controls.
b. Review
and approve all transactions between the Company and any related person that
are
required to be disclosed pursuant to SEC Regulation S-K, Item 404 (“Item 404”),
after reviewing each such transaction for potential conflicts of interests
and
other improprieties. “Related person” and “transaction” shall have the meanings
given to such terms in Item 404, as amended from time to time.
c. Establish
procedures for the receipt, retention and treatment of complaints received
by
the Company regarding accounting, internal accounting controls or auditing
matters, and the confidential, anonymous submission by employees of the Company
of concerns regarding questionable accounting or auditing matters. Adopt, as
necessary, appropriate remedial measures or actions with respect to such
complaints or concerns.
d. As
requested by the Board, review and investigate conduct alleged by the Board
to
be in violation of the Company’s Code of Conduct, and adopt as necessary or
appropriate, remedial, disciplinary, or other measures with respect to such
conduct.
e. Prepare
the report required by the rules of the SEC to be included in the Company’s
annual proxy statement.
f. Regularly
report to the Board on the Audit Committee’s activities, recommendations and
conclusions.
g. Review
and reassess the Charter’s adequacy as appropriate and recommend any proposed
changes to the Board for approval.
h. Review
the eligibility of each member of the Audit Committee against current regulatory
standards, including the continuing eligibility of the audit committee financial
expert.
a. Meet
with
the financial and control officers of the Company or any other persons it deems
necessary or appropriate in discharging its duties. The Committee shall have
direct access to all such persons, including the internal auditors, with and
without management present.
D. LIMITATION
OF DUTIES
The
Audit
Committee's responsibility is oversight. Management of the Company has the
responsibility for the Company's financial statements as well as the Company's
financial reporting process, principles and internal controls. The external
auditors are responsible for performing an audit of the Company's annual
financial statements, expressing an opinion as to the conformity of such annual
financial statements with generally accepted accounting principles, reviewing
the Company's quarterly financial statements and other procedures. It is
recognized that it is not the duty of the Audit Committee to plan or conduct
audits or to determine that the Company's financial statements fairly present
the Company's financial position and results of operation and are in accordance
with generally accepted accounting principles and applicable laws and
regulations. Each member of the Audit Committee shall be entitled to rely on
(i)
the integrity of those persons within the Company and of the professionals
and
experts (such as the external auditors) from which it receives information,
(ii)
the accuracy of the financial and other information provided to the Audit
Committee by such persons, professionals or experts absent actual knowledge
to
the contrary and (iii) representations made by management or the external
auditor as to any information technology services of the type described in
Rule
2-01(c)(4)(ii) of Regulation S-X and other non-audit services provided by the
Company's external auditors. In carrying out its responsibilities, the Audit
Committee believes its policies and procedures should remain flexible to best
react to a changing environment.
E. FUNDING
AND ADDITIONAL POWERS
The
Company shall provide appropriate funding, as determined by the Audit Committee,
to permit the Audit Committee to perform its duties under this Charter, to
compensate its advisors and to compensate any registered public accounting
firm
engaged for the purpose of rendering or issuing an audit report or related
work
or performing other audit, review or attest services for the Company. The Audit
Committee, at its discretion, has the authority to initiate special
investigations, and, hire special legal, accounting or other outside advisors
or
experts to assist the Audit Committee, as it deems necessary to fulfill its
duties under this Charter. The Audit Committee may also perform such other
activities consistent with this Charter, the Company’s Bylaws and governing law,
as the Committee or the Board deems necessary or appropriate.
F. MEETINGS
The
Audit
Committee shall meet as often as it determines, but not less frequently than
quarterly. A majority of the members shall represent a quorum of the Audit
Committee, and, if a quorum is present, any action approved by at least a
majority of the members present shall represent the valid action of the Audit
Committee. The Audit Committee may form and delegate authority to subcommittees,
or to one or more members of the Audit Committee, when appropriate. The Audit
Committee shall meet with management, and the independent auditor in separate
executive sessions as appropriate. The Audit Committee shall meet with the
independent auditor and management on a quarterly basis to review the Company’s
financial statements and financial reports. The Audit Committee shall maintain
written minutes of its meetings, which minutes will be filed with the minutes
of
the meetings of the Board.
Annex
B
CHARTER
OF THE COMPENSATION COMMITTEE
OF
THE
BOARD
OF DIRECTORS
OF
NUTRACEA
I. PURPOSE
This
Charter specifies the scope of the responsibilities of the Compensation
Committee (the “Committee”) of the Board of Directors (the “Board”) of NutraCea
(the “Company”) and the manner in which those responsibilities shall be
performed, including its structure,
processes and membership requirements.
The
primary purpose of the Committee is to discharge the Board’s responsibilities
relating
to compensation and benefits of the Company’s executive officers and directors.
In carrying
out these responsibilities, the Committee shall review all components of
executive officer and director compensation for consistency with the Committee’s
compensation philosophy
as in effect from time to time.
The
Committee is
also
responsible for producing an annual report on executive compensation for
inclusion in the Company’s proxy statement, in accordance with applicable
rules
and
regulations.
II. ORGANIZATION
AND MEMBERSHIP REQUIREMENTS
The
Committee shall be comprised of at least three directors, each of whom shall
satisfy the independence requirements of The Nasdaq Stock Market, Section 162(m)
of the Internal Revenue
Code of 1986 and the rules promulgated by the Securities and Exchange Commission
under
Section 16(b) of the Securities Exchange Act of 1934, as amended; provided
that
one director who does not meet the independence criteria of Nasdaq may, subject
to approval of the Board, serve on the Committee pursuant to the limitations
under the “exceptional and limited circumstances”
exception as provided under the rules of Nasdaq. A director shall not serve
as a
member
of
the Committee if the Chief Executive Officer or another executive officer of
the
Company serves on the compensation committee of another company that employs
that director as
an
executive officer.
The
members shall be appointed by the Board and shall serve until their successors
are duly
elected and qualified or their earlier resignation or removal. Any member of
the
Committee may be replaced by the Board. Unless a chairman is elected by the
Board, the members of the Committee
may designate a chairman by the majority vote of the full Committee membership.
The Committee may from time to time delegate duties or responsibilities to
subcommittees or to one
member of the Committee.
A
majority of the members shall represent a quorum of the Committee, and, if
a
quorum is
present, any action approved by at least a majority of the members shall
represent the valid action
of
the Committee. Any actions taken by the Committee during any period in which
one
or more
members fail for any reason to meet the membership requirements set forth above
shall be nonetheless
duly authorized actions of the Committee for all corporate
purposes.
The
Committee shall have the authority to obtain advice or assistance from
consultants, legal counsel, accounting or other advisors as appropriate, to
perform its duties hereunder and to determine
the terms, costs and fees for such engagements. Without limitation, the
Committee shall
have the sole authority to retain or terminate any consulting firm used to
evaluate director, CEO or executive compensation, and to determine and approve
the terms of engagement the fees and
costs
for such engagements. The fees and costs of any consultant or advisor engaged
by
the Committee to assist in it in performing any duties hereunder shall be borne
by the Company.
The
Committee shall meet as often as it deems appropriate, but not less frequently
than once each year, to review the compensation of the executive officers,
directors and other employees of the Company, and otherwise perform its duties
under this charter.
The
Committee shall maintain written minutes of its meetings, which minutes will
be
filed
with the minutes of the meetings of the Board.
IV. |
COMMITTEE
AUTHORITY AND RESPONSIBILITIES
|
To
fulfill its responsibilities and duties, the Committee shall:
1. Determine
all compensation for the Chief Executive Officer, including
incentive-based
and
equity-based compensation. The Chief Executive Officer may not be present during
such voting or deliberations.
2. Review
and approve annual performance objectives and goals relevant to compensation
for the Chief Executive Officer and evaluate the performance of the Chief
Executive Officer in light of these goals and objectives.
3. Consider,
in determining the long-term incentive component of compensation for the
Chief
Executive Officer, the Company’s performance and relative shareholder return,
the value of similar incentive awards to chief executive officers at comparable
companies, and the awards given
to
the Company’s Chief Executive Officer in past years.
4. Make
recommendations to the Board regarding incentive-based or equity-based
compensation plans in which the Company’s executive officers participate, and
review and approve salaries, incentive and equity awards for other executive
officers and employees and oversee
the evaluation of management.
5. Approve
all employment, severance, or change-in-control agreements, special or
supplemental
benefits, or provisions including the same, applicable to executive
officers.
6. Periodically
review and advise the Board concerning both regional and industry-wide
compensation
practices and trends in order to assess the adequacy and competitiveness of
the
Company’s compensation programs for the CEO, other executive officers and
directors relative to
comparable companies in the Company’s industry.
7. Review
and propose to the Board from time to time changes in director compensation.
8. Prepare
an annual report on executive compensation for inclusion in the Company’s
proxy
statement for the annual meeting of stockholders, in accordance with applicable
rules and regulations.
9. Perform
such other activities consistent with this Charter, the Company’s By Laws
and
governing law, as the Committee or the Board deems necessary or
appropriate.
10. Make
regular reports to the Board of Directors regarding the foregoing.
11. Review
and reassess the adequacy of this Charter as appropriate and recommend any
proposed
changes to the Board for approval.
12. Review
and evaluate the Committee’s own performance on an annual basis.
Annex
C
CHARTER
OF THE NOMINATING & CORPORATE GOVERNANCE COMMITTEE
OF
THE
BOARD
OF DIRECTORS
OF
NUTRACEA
A. Authority
|
1.
|
The
Board of Directors (the "Board") of NutraCea (the "Company") has
established the Nominating & Corporate Governance Committee (the
"Committee") with oversight responsibilities as described in this
Charter
of the Nominating & Corporate Governance Committee (this "Charter") or
as additionally requested by the
Board.
|
|
2.
|
The
Committee shall identify and assess individuals qualified to serve
as
directors on the Board and to select or to recommend that the Board
select, the director nominees for the next Annual Meeting of the
Stockholders, and develop and recommend to the Board a set of corporate
governance principles applicable to the
Company.
|
|
3.
|
The
Committee is empowered to retain persons having special competence
and
expertise as necessary to assist the Committee in fulfilling its
responsibilities pursuant to the requirements of this Charter, and
the
rules and regulations of the Securities and Exchange Commission ("SEC")
and the
rules and regulations of other regulatory organizations to which
the
Company is subject,
all with authorization and concurrence of the Board.
|
B. Purpose
The
purpose of the Committee includes, but is not limited to:
|
1.
|
Identifying
and recommending to the Board qualified potential director nominees
for
election at each of the Company's Annual Meeting of the
Stockholders.
|
|
2.
|
Recommending
to the Board those directors that should serve as members and chairpersons
of the committees of the Board.
|
|
3.
|
Developing
and recommending to the Board the Company's corporate governance
policies
and procedures.
|
|
4.
|
Recommending
to the Board the compensation for members and chairpersons of the
Board's
committees.
|
C. Membership
|
1.
|
The
members of the Committee shall be appointed by the Board. Consistent
with
the rules and regulations of the SEC and of
other regulatory organizations to which the Company is
subject,
as
appropriate, the Committee will consist of not less than three Directors,
each of whom, shall satisfy the independence requirements established
by
the rules of the Securities and Exchange Commission and the rules
of any
market or exchange on which the Company’s common stock is then listed or
quoted for trading (“Trading Market”); provided that one director who does
not meet the Trading Market independence criteria may, subject to
the
approval of the Board, serve on the Committee pursuant to any exception
as
provided under the rules of the Trading Market.
|
|
2.
|
The
Committee members will be free from any financial, family or other
material personal relationship that, in the opinion of the Board
or the
other Committee members, would interfere with the exercise of such
member's independence from the Company and the Company's
management.
|
|
3.
|
All
members of the Committee must have sufficient expertise in the area
of
director selection and/or corporate governance, as determined by
the Board
in its business judgment, to discharge the responsibilities of the
Committee as set forth in this Charter, or must acquire such expertise
within a reasonable period of time after his or her appointment to
the
Committee.
|
|
4.
|
The
Chairperson of the Committee shall be designated by the Board.
|
D. Term
|
1.
|
The
Board will appoint the members of the Committee, including the
chairperson, annually at its organizational
meeting.
|
|
2.
|
During
their annual term, members
of the Committee may be removed only by the affirmative vote of a
majority
of the Board.
|
E. Meetings
|
1.
|
The
Committee shall meet at least once annually and otherwise as the
members
of the Committee deem necessary or appropriate.
|
|
2.
|
The
majority of the members shall represent a quorum of the Committee,
and, if
a quorum is present, any action approved by at least a majority of
the
members present shall represent the valid action of the
Committee.
|
|
3.
|
The
Committee shall maintain written minutes of it meetings, which minutes
will be filed with the minutes of the meetings of the
Board.
|
F. Reporting
and Communications; Responsibilities of the Nominating & Corporate
Governance Committee
The
policies and procedures by which the Committee executes its responsibilities
pursuant to this Charter shall be flexible in order to best respond to changing
conditions and to ensure that the Company's corporate governance policies and
procedures continue to effectively and efficiently promote the interests of
the
Company's and its stockholders. The Committee may not delegate any of its
responsibilities to management, but may delegate any of its responsibilities
to
subcommittees consisting solely of two or more members of the
Committee.
In
carrying out its responsibilities, the Committee shall:
|
1.
|
Board
Candidates and Nominees.
|
|
a.
|
Establish
and communicate to stockholders a method for stockholders to recommend
potential director nominees for the Committee's consideration.
|
|
b.
|
Develop
reasonable criteria for selection of director nominees.
|
|
c.
|
Conduct
appropriate inquiries into the backgrounds and qualifications of
potential
director nominees.
|
|
d.
|
Identify
and recommend to the Board qualified potential director nominees
who bring
knowledge, experience and expertise that would benefit the Board,
the
Company and its stockholders, as determined advisable by the
Committee.
|
|
a.
|
Plan
for continuity on the Board as directors are scheduled to retire
from the
Board.
|
|
b.
|
Review
and recommend to the Board an appropriate course of action with respect
to
or upon the resignation, retirement or removal of any director, including
whether a new director should be appointed by the Board prior to
the
Company's next Annual Meeting of Stockholders.
|
|
c.
|
From
time to time as the Committee determines it to be necessary or
appropriate,
review and recommend to the Board changes to the size of the Board
and its
committees.
|
|
d.
|
From
time to time as the Committee determines it to be necessary or
appropriate,
review and recommend to the Board changes to policy matters pertaining
to
the roles, responsibilities, retirement age, term limits and removal
of
directors.
|
|
e.
|
Oversee
management's establishment of and, from time to time as the Committee
determines it to be necessary or appropriate, review the effectiveness
of
the Company's new director orientation program and continuing director
education program.
|
|
f.
|
From
time to time as the Committee determines it to be necessary or
appropriate, review all Board committees and their charters and,
as
necessary, recommend to the Board changes in the committee charters
or the
responsibilities or number of committees.
|
|
g.
|
From
time to time as the Committee determines it to be necessary or
appropriate, recommend that the Board establish a new or special
committee
of the Board that may be necessary to properly address ethical, legal
or
other matters that may arise.
|
|
h.
|
On
an annual basis, determine and propose to the Board which directors
should
serve as members and chairpersons of the Board committees. In
making its determinations, the Committee shall consider at least
the
following: (i) balancing the benefits derived from continuity against
the benefits derived from the diversity of experience and viewpoints
that
may result from the rotation of committee members and chairpersons;
(ii)
subject matter expertise; (iii) applicable legal or other
requirements; (iv) tenure; (v) the desires of individual members
of the
Board; (vi) as applicable, the independence standards applicable
to the
members of such committees; and (vii) such criteria, factors and
circumstances as it determines to be necessary or
appropriate.
|
|
i.
|
On
an annual basis, review the compensation attributable to service
as a
member of the Board, or as a member or chairperson of its committees,
and
recommend to the Board the compensation payable for the following
year. As
necessary, review any special compensation which might be paid to
a member
of the Board or one of its committees, and recommend to the Board
such
compensation.
|
|
j.
|
From
time to time as the Committee determines it to be necessary or
appropriate, review the qualifications and performance of any members
of
the Board. As incumbent directors are eligible for re-election under
the
terms of their prior election, consider whether to recommend each
incumbent director for re-election.
|
|
k.
|
On
an annual basis, conduct an assessment of the Board's performance
during
the previous year. The purpose of this assessment is to increase
the
effectiveness of the Board and its members. In conducting such
assessments, the Committee shall consider such criteria, factors
and
circumstances as they determine to be necessary or
appropriate.
|
|
l.
|
On
an annual basis, conduct a self-assessment of its performance during
the
previous year. The purpose of this assessment is to increase the
effectiveness of the Committee and its members. Compliance with the
responsibilities listed in this Charter shall form the principal
criteria
for such assessments, as well as such other factors and circumstances
as
are determined appropriate by the Committee or the Board.
|
|
3.
|
Governance
Principles.
|
|
a.
|
Develop
and recommend to the Board a set of corporate governance principles
that
complies with the rules and regulations and the SEC and of
other regulatory organizations to which the Company is subject.
Such corporate governance principles shall address at least the following:
(i) director qualification standards; (ii) director responsibilities;
(iii) director access to management and, as necessary and
appropriate, independent advisors; (iv) director compensation; (v)
director orientation and continuing education; (vi) management succession;
and (vii) annual performance evaluation of the Board.
|
|
b.
|
At
least annually, review such corporate governance practices and procedures
and take such actions as the Committee deems necessary or
appropriate.
|
|
c.
|
Review
and make recommendations to the Board regarding stockholders' proposals
that relate to corporate governance.
|
|
4.
|
Code
of Conduct and Ethics.
|
|
a.
|
Develop
and recommend to the Board a Code of Conduct and Ethics (the "Code
of
Conduct") that complies with the rules and regulations of the SEC
and
of
other regulatory organizations to which the Company is subject.
Such Code of Conduct shall address at least the following: (i) conflicts
of interest; (ii) corporate opportunities; (iii) confidentiality;
(d) fair
dealing; (iv) protection and proper use of Company assets; (v) compliance
with laws, rules and regulations (including insider trading laws);
(vi)
encouraging the reporting of any illegal or unethical behavior; and
(vii)
such issues related to the Company's senior financial officers as
required
by the SEC.
|
|
b.
|
At
least annually, review the Code of Conduct and take such actions
as the
Corporate Governance Committee deems necessary or appropriate.
|
|
a.
|
From
time to time as the Committee determines it to be necessary or
appropriate, it may select and retain independent counsel or other
advisors, including a search firm to help identify new potential
director
nominees or to provide independent advice to the Committee. The Committee
shall have the sole authority to retain (on terms established solely
by
the Committee), terminate and approve the fees of any such counsel
and
advisors. The Committee may meet with any such counsel or advisors
without
management present. The Company will bear the cost of such counsel
and
advisors.
|
|
b.
|
The
Committee shall, as it deems it to be necessary or appropriate, consider
and approve or disapprove any and all transactions involving the
Company
and any director, executive officer, senior financial officer or
any
related party and other questions of actual and potential conflicts
of
interest or appearances of impropriety of or involving the Company's
directors, executive officers or senior financial officers or any
related
party as they may arise, from time to time, and, when determined
to be
necessary or appropriate, issue to a director, executive officer
or senior
financial officer instructions on how to conduct himself/herself
in such
matters so as to ensure that the best interests of the Company are
protected.
|
|
c.
|
In
considering all such matters, the Committee shall consider at least
the
following: (i) whether or not the relationship or transaction is
on terms
and conditions not materially less favorable to the Company than
could be
obtained from an independent third party (including obtaining independent
support for such conclusion); (ii) the reasons for and the benefits
obtainable by the Company from such relationship or transaction;
(iii) the
impact of such relationship or transaction on the director's or officer's
ability to continue to serve the best interests of the Company; and
(iv)
anticipated stockholder reaction to such relationship or transaction.
The
Committee shall ensure that all approved related party transactions
or
other actual and potential conflicts of interest or appearances of
impropriety, to the extent determined material, are properly disclosed
to
the Company's stockholders in accordance with applicable
requirements.
|
|
d.
|
From
time to time as the Committee determines it to be necessary or
appropriate, consult with the Company's General Counsel and outside
legal
counsel, if determined necessary or appropriate, with respect to
the terms
and conditions of the Company's Certificate of Incorporation and
Bylaws as
they relate to corporate governance matters and take such actions
as the
Corporate Governance Committee deems necessary or appropriate, subject
to
Board and stockholder approval, if applicable, in accordance with
the
Company's Bylaws and applicable law.
|
|
e.
|
Promptly
make available the minutes of all meetings of the Committee to the
Board
and report the Committee's activities to the Board at the Board's
meeting
next following each Committee meeting so that the Board is kept fully
informed of the Committee's activities on a current basis.
|
|
f.
|
From
time to time as the Committee determines it to be necessary or
appropriate, conduct such reviews, investigations and surveys and
take
such action as the Committee may consider necessary or appropriate
in the
exercise of its duties and responsibilities.
|
Annex
D
NUTRACEA
2005 EQUITY INCENTIVE PLAN
As
Amended April 18, 2007
1. PURPOSE.
The
purpose of this Plan is to provide incentives to attract, retain and motivate
eligible persons whose present and potential contributions are important to
the
success of the Company, its Parent, Subsidiaries and Affiliates, by offering
them an opportunity to participate in the Company's future performance through
awards of Options, Restricted Stock and Stock Bonuses. Capitalized terms not
defined in the text are defined in Section 24.
2. SHARES SUBJECT TO THE PLAN.
2.1 Number of Shares Available.
Subject
to Sections 2.2 and 18, the total number of Shares reserved and available for
grant and issuance pursuant to this Plan will be 10,000,000. Subject to Sections
2.2 and 18, Shares that: (a) are subject to issuance upon exercise of an Option
but cease to be subject to such Option for any reason other than exercise of
such Option; (b) are subject to an Award granted hereunder but are forfeited
or
are repurchased by the Company at the original issue price; or (c) are subject
to an Award that otherwise terminates without Shares being issued; will again
be
available for grant and issuance in connection with future Awards under this
Plan. In order that ISO’s may be granted under this Plan, no more than
10,000,000 Shares shall be issued as ISOs. At all times the Company shall
reserve and keep available a sufficient number of Shares as shall be required
to
satisfy the requirements of all outstanding Options granted under this Plan
and
all other outstanding but unvested Awards granted under this Plan.
2.2 Adjustment of Shares.
In the
event that the number of outstanding Shares is changed by a stock dividend,
recapitalization, stock split, reverse stock split, subdivision, combination,
reclassification or similar change in the capital structure of the Company
without consideration, then (a) the number of Shares reserved for issuance
under
this Plan, (b) the Exercise Prices of and number of Shares subject to
outstanding Options, (c) the maximum number of Shares that may be issued as
ISOs
set forth in Section 2.1, and (d) the number of Shares subject to other
outstanding Awards will be proportionately adjusted, subject to any required
action by the Board or the shareholders of the Company and compliance with
applicable securities laws; provided,
however,
that
fractions of a Share will not be issued but will either be replaced by a cash
payment equal to the Fair Market Value of such fraction of a Share or will
be
rounded up to the nearest whole Share, as determined by the
Committee.
3. ELIGIBILITY.
ISOs
(as defined in Section 5 below) may be granted only to employees (including
officers and directors who are also employees) of the Company or of a Parent
or
Subsidiary of the Company. All other Awards may be granted to employees,
officers, directors, consultants and advisors of the Company or any Parent,
Subsidiary or Affiliate of the Company; provided such consultants and advisors
render bona fide services not in connection with the offer and sale of
securities in a capital-raising transaction. A person may be granted more than
one Award under this Plan.
4. ADMINISTRATION.
4.1 Committee Authority.
This
Plan will be administered by the Committee or by the Board acting as the
Committee. Subject to the general purposes, terms and conditions of this Plan,
and to the direction of the Board, the Committee will have full power to
implement and carry out this Plan. Without limitation, the Committee will have
the authority to:
|
(a)
|
construe
and interpret this Plan, any Award Agreement and any other agreement
or
document executed pursuant to this Plan;
|
|
(b)
|
prescribe,
amend and rescind rules and regulations relating to this Plan;
|
|
(c)
|
select
persons to receive Awards;
|
|
(d)
|
determine
the form and terms of Awards (which need not be identical), including
but
not limited to, the time or times at which Options shall be exercisable
and the extension or acceleration of any such provisions or limitations,
based in each case on such factors as the Committee shall determine,
in
its sole discretion;
|
|
(e)
|
determine
the number of Shares or other consideration subject to
Awards;
|
|
(f)
|
determine
whether Awards will be granted singly, in combination with, in tandem
with, in replacement of, or as alternatives to, other Awards under
this
Plan or any other incentive or compensation plan of the Company or
any
Parent, Subsidiary or Affiliate of the
Company;
|
|
(g)
|
grant
waivers of Plan or Award
conditions;
|
|
(h)
|
determine
the vesting, exercisability and payment of
Awards;
|
|
(i)
|
correct
any defect, supply any omission or reconcile any inconsistency in
this
Plan, any Award or any Award
Agreement;
|
|
(j)
|
determine
whether an Award has been earned;
and
|
|
(k)
|
make
all other determinations necessary or advisable for the administration
of
this Plan.
|
4.2 Committee Discretion.
Any
determination made by the Committee with respect to any Award will be made
in
its sole discretion at the time of grant of the Award or, unless in
contravention of any express term of this Plan or Award, at any later time,
and
such determination will be final and binding on the Company and on all persons
having an interest in any Award under this Plan. The Committee may delegate
to
one or more officers of the Company the authority to grant an Award under this
Plan to Participants who are not Insiders of the Company.
4.3 Compliance
with Code Section 162(m).
If two
or more members of the Board are “outside directors” within the meaning of
Section 162(m) of the Code (“Outside
Directors”),
the
Committee shall be comprised of at least two members of the Board, all of whom
are Outside Directors.
5. OPTIONS.
The
Committee may grant Options to eligible persons and will determine whether
such
Options will be Incentive Stock Options within the meaning of the Code
("ISOs")
or
Nonqualified Stock Options ("NQSOs"),
the
number of Shares subject to the Option, the Exercise Price of the Option, the
period during which the Option may be exercised, and all other terms and
conditions of the Option, subject to the following:
5.1 Form of Option Grant.
Each
Option granted under this Plan will be evidenced by an Award Agreement which
will expressly identify the Option as an ISO or an NQSO ("Stock
Option Agreement"),
and
will be in such form and contain such provisions (which need not be the same
for
each Participant) as the Committee may from time to time approve, and which
will
comply with and be subject to the terms and conditions of this
Plan.
5.2 Date of Grant.
The
date of grant of an Option will be the date on which the Committee makes the
determination to grant such Option, unless otherwise specified by the Committee.
The Stock Option Agreement and a copy of this Plan will be delivered to the
Participant within a reasonable time after the granting of the
Option.
5.3 Exercise Period
and Expiration Date.
An
Option will vest and become exercisable within the times or upon the occurrence
of events determined by the Committee and set forth in the Award Agreement
governing such Options, subject to the provisions of Section 5.6, and subject
to
Company policies established by the Committee from time to time. The Committee
may provide for Options to vest and become exercisable at one time or from
time
to time, periodically or otherwise, in such number of Shares or percentage
of
Shares subject to the Option as the Committee determines. However, except in
the
case of Options granted to Officers, Directors, and Consultants, Options shall
become exercisable at a rate of no less than 20% per year over five (5) years
from the date the Options are granted.
No
Option
will be exercisable after the expiration of ten (10) years from the date the
Option is granted; and provided
further
that no
ISO granted to a person who directly or by attribution owns more than ten
percent (10%) of the total combined voting power of all classes of stock of
the
Company or of any Parent or Subsidiary of the Company ("Ten Percent Shareholder")
will be
exercisable after the expiration of five (5) years from the date the ISO is
granted.
5.4 Exercise Price.
The
Exercise Price of an NQSO will be determined by the Committee when the Option
is
granted; provided,
however,
that if
expressly required by one or more state securities authorities or laws as a
condition of issuing Awards and Shares in compliance with the securities laws
of
such state, the exercise price of an NQSO shall not be less than 85% of the
Fair
Market Value of the Shares on the date of grant and the Exercise Price of any
NQSO granted to a Ten Percent Shareholder shall not be less than 110% of the
Fair Market Value of the Shares on the date of grant. Notwithstanding the
foregoing, an NQSO may be granted with an exercise price lower than that set
forth in the preceding sentence if such Option is granted pursuant to an
assumption or a substitution for another Option in a manner consistent with
the
provisions of Section 424(a) of the Code. The Exercise Price of an ISO will
be
not less than 100% of the Fair Market Value of the Shares on the date of grant
and the Exercise Price of any ISO granted to a Ten Percent Shareholder will
not
be less than 110% of the Fair Market Value of the Shares on the date of grant.
Notwithstanding the foregoing, an ISO may be granted with an exercise price
lower than that set forth in the preceding sentence if such Option is granted
pursuant to an assumption or a substitution for another Option in a manner
consistent with the provisions of Section 424(a) of the Code. Payment for the
Shares purchased may be made in accordance with Section 8 of this
Plan.
5.5 Method of Exercise.
Options
may be exercised only by delivery to the Company of a written stock option
exercise agreement (the "Exercise Agreement")
in a
form approved by the Committee (which need not be the same for each
Participant), stating the number of Shares being purchased, the restrictions
imposed on the Shares purchased under such Exercise Agreement, if any, and
such
representations and agreements regarding Participant's investment intent and
access to information and other matters, if any, as may be required or desirable
by the Company to comply with applicable securities laws, together with payment
in full of the Exercise Price for the number of Shares being
purchased.
5.6 Termination.
Notwithstanding the exercise periods set forth in the Stock Option Agreement,
exercise of an Option will always be subject to the following:
|
(a)
|
If
the Participant is Terminated for any reason except death or Disability,
then the Participant may exercise such Participant's Options only
to the
extent that such Options would have been exercisable upon the Termination
Date no later than thirty (30) days after the Termination Date (or
such
longer time period not exceeding five (5) years as may be determined
by
the Committee, with any exercise beyond three (3) months after the
Termination Date deemed to be an NQSO), but in any event, no later
than
the expiration date of the Options.
|
|
(b)
|
If
the Participant is Terminated because of Participant's death or Disability
(or the Participant dies within three (3) months after a Termination
other
than because of Participant's Disability), then Participant's Options
may
be exercised only to the extent that such Options would have been
exercisable by Participant on the Termination Date and must be exercised
by Participant (or Participant's legal representative or authorized
assignee) no later than twelve (12) months after the Termination
Date (or
such shorter (but not less than six months) or longer time period
not
exceeding five (5) years as may be determined by the Committee, with
any
such exercise beyond (a) three (3) months after the Termination Date
when
the Termination is for any reason other than the Participant's death
or
“disability,” as defined in Section 22(e)(3) of the Code, or (b) twelve
(12) months after the Termination Date when the Termination is for
Participant's death or Disability, deemed to be an NQSO), but in
any event
no later than the expiration date of the
Options.
|
|
(c)
|
Notwithstanding
the provisions in paragraphs 5.6(a) and (b) above, Award Agreements
and
other agreements relating to Awards under this Plan may include a
provision that if a Participant is terminated for Cause, neither
the
Participant, the Participant’s estate nor such other person who may then
hold the Option shall be entitled to exercise any Option with respect
to
any Shares whatsoever, after termination of service, whether or not
after
termination of service the Participant may receive payment from the
Company or a Subsidiary for vacation pay, for services rendered prior
to
termination, for services rendered for the day on which termination
occurs, for salary in lieu of notice, or for any other benefits.
For the
purpose of this paragraph, termination of service shall be deemed
to occur
on the date when the Company dispatches notice or advice to the
Participant that Participant’s service is
terminated.
|
5.7 Limitations on Exercise.
The
Committee may specify a reasonable minimum number of Shares that may be
purchased on any exercise of an Option, provided that such minimum number will
not prevent Participant from exercising the Option for the full number of Shares
for which it is then exercisable.
5.8 Limitations on ISOs.
The
aggregate Fair Market Value (determined as of the date of grant) of Shares
with
respect to which ISOs are exercisable for the first time by a Participant during
any calendar year (under this Plan or under any other incentive stock option
plan of the Company or any Affiliate, Parent or Subsidiary of the Company)
will
not exceed $100,000. If the Fair Market Value of Shares on the date of grant
with respect to which ISOs are exercisable for the first time by a Participant
during any calendar year exceeds $100,000, then the Options for the first
$100,000 worth of Shares to become exercisable in such calendar year will be
ISOs and the Options for the amount in excess of $100,000 that become
exercisable in that calendar year will be NQSOs. In the event that the Code
or
the regulations promulgated thereunder are amended after the Effective Date
of
this Plan to provide for a different limit on the Fair Market Value of Shares
permitted to be subject to ISOs, such different limit will be automatically
incorporated herein and will apply to any Options granted after the effective
date of such amendment.
5.9 Modification, Extension or Renewal.
The
Committee may modify, extend or renew outstanding Options and authorize the
grant of new Options in substitution therefor, provided that any such action
may
not, without the written consent of a Participant, impair any of such
Participant's rights under any Option previously granted. Any outstanding ISO
that is modified, extended, renewed or otherwise altered will be treated in
accordance with Section 424(h) of the Code. The Committee may reduce the
Exercise Price of outstanding Options without the consent of Participants
effected by a written notice to them; provided,
however,
that
the Exercise Price may not be reduced below the minimum Exercise Price that
would be permitted under Section 5.4 of this Plan for Options granted on the
date the action is taken to reduce the Exercise Price.
5.10 No Disqualification.
Notwithstanding any other provision in this Plan, no term of this Plan relating
to ISOs will be interpreted, amended or altered, nor will any discretion or
authority granted under this Plan be exercised, so as to disqualify this Plan
under Section 422 of the Code or, without the consent of the Participant
affected, to disqualify any ISO under Section 422 of the Code.
5.11 Automatic
Grant Program for Non-Employee Directors.
Each
Non-employee Director shall be eligible to receive Options under the automatic
option grant program described below (the Program”).
|
(a)
|
Annual
Grants.
On the date of each of the Company's annual meetings of shareholders,
if
the Non-Employee Director is still a member of the Board after
the
meeting, the Optionee will automatically be granted an NQSO for
35,000
Shares (a "Annual
Grant").
|
|
(b)
|
Vesting.
Options granted under the Program shall be exercisable as they
vest. The
date an Optionee receives an Annual Grant is referred to as the
"Start
Date"
for such Option. Each Annual Grant will vest as to 1/12th
of
the Shares subject to such grant monthly following the Start
Date. |
|
(c)
|
Exercise Price.
The exercise price of an Option granted under the Program shall
be the
Fair Market Value of the Shares, at the time that the Option
is
granted. |
|
(d)
|
Termination of Option.
Except as provided below in this Section, each Option shall
expire ten
(10) years after its Start Date (the "Expiration
Date").
The Option shall cease to vest if the Optionee ceases to be
a member of
the Board. The date on which the Optionee ceases to be a member
of the
Board shall be referred to in this Section as the "Termination
Date".
An Option may be exercised after the Termination Date only
as set forth
below: |
|
(e)
|
If the Optionee ceases to be a member
of the Board for
any reason, then each Option then held by such Optionee,
to the extent
(and only to the extent) that it would have been exercisable
by the
Optionee on the Termination Date, may be exercised by the
Optionee (or the
Optionee's legal representative) within ninety (90) days
after the
Termination Date (or such shorter or longer period as is
specified in the
Option Agreement), but in no event later than the Expiration
Date. |
6. RESTRICTED STOCK.
A
Restricted Stock Award is an offer by the Company to sell to an eligible person
Shares that are subject to restrictions. The Committee will determine to whom
an
offer will be made, the number of Shares the person may purchase, the price
to
be paid (the "Purchase Price"),
the
restrictions to which the Shares will be subject, if any, and all other terms
and conditions of the Restricted Stock Award, subject to the
following:
6.1 Form of Restricted Stock Award.
All
purchases under a Restricted Stock Award made pursuant to this Plan will be
evidenced by an Award Agreement ("Restricted
Stock Purchase Agreement")
that
will be in such form (which need not be the same for each Participant) as the
Committee will from time to time approve, and will comply with and be subject
to
the terms and conditions of this Plan. The offer of Restricted Stock will be
accepted by the Participant's execution and delivery of the Restricted Stock
Purchase Agreement and full payment for the Shares to the Company within thirty
(30) days from the date the Restricted Stock Purchase Agreement is delivered
to
the person. If such person does not execute and deliver the Restricted Stock
Purchase Agreement along with full payment for the Shares to the Company within
thirty (30) days, then the offer will terminate, unless otherwise determined
by
the Committee.
6.2 Purchase Price.
The
Purchase Price of Shares sold pursuant to a Restricted Stock Award will be
determined by the Committee; provided,
that if
expressly required by any state securities authorities as a condition of the
offer and sale of Shares subject to Restricted Stock Awards in compliance with
the securities laws of such state, the Purchase Price will be at least 85%
of
the Fair Market Value of the Shares on the date the Restricted Stock Award
is
granted, except in the case of a sale to a Ten Percent Shareholder, in which
case the Purchase Price will be 100% of the Fair Market Value. Payment of the
Purchase Price may be made in accordance with Section 8 of this
Plan.
6.3 Restrictions.
Restricted Stock Awards will be subject to such restrictions (if any) as the
Committee may impose. The Committee may provide for the lapse of such
restrictions in installments and may accelerate or waive such restrictions,
in
whole or part, based on length of service, performance or such other factors
or
criteria as the Committee may determine.
7. STOCK BONUSES.
7.1 Awards of Stock Bonuses.
A Stock
Bonus is an award of Shares (which may consist of Restricted Stock) for services
rendered to the Company or any Parent, Subsidiary or Affiliate of the Company.
A
Stock Bonus may be awarded for past services already rendered to the Company,
or
any Parent, Subsidiary or Affiliate of the Company (provided that the
Participant pays the Company the par value, if any, of the Shares awarded by
such Stock Bonus in cash) pursuant to an Award Agreement (the "Stock Bonus Agreement")
that
will be in such form (which need not be the same for each Participant) as the
Committee will from time to time approve, and will comply with and be subject
to
the terms and conditions of this Plan. A Stock Bonus may be awarded upon
satisfaction of such performance goals as are set out in advance in the
Participant's individual Award Agreement (the "Performance Stock Bonus Agreement")
that
will be in such form (which need not be the same for each Participant) as the
Committee will from time to time approve, and will comply with and be subject
to
the terms and conditions of this Plan. Stock Bonuses may vary from Participant
to Participant and between groups of Participants, and may be based upon the
achievement of the Company, Parent, Subsidiary or Affiliate and/or individual
performance factors or upon such other criteria as the Committee may determine.
7.2 Terms of Stock Bonuses.
The
Committee will determine the number of Shares to be awarded to the Participant
and whether such Shares will be Restricted Stock. If the Stock Bonus is being
earned upon the satisfaction of performance goals pursuant to a Performance
Stock Bonus Agreement, then the Committee will determine: (a) the nature, length
and starting date of any period during which performance is to be measured
(the
"Performance Period")
for
each Stock Bonus; (b) the performance goals and criteria to be used to measure
the performance, if any; (c) the number of Shares that may be awarded to the
Participant; and (d) the extent to which such Stock Bonuses have been earned.
Performance Periods may overlap and Participants may participate simultaneously
with respect to Stock Bonuses that are subject to different Performance Periods
and different performance goals and other criteria. The number of Shares may
be
fixed or may vary in accordance with such performance goals and criteria as
may
be determined by the Committee. The Committee may adjust the performance goals
applicable to the Stock Bonuses to take into account changes in law and
accounting or tax rules and to make such adjustments as the Committee deems
necessary or appropriate to reflect the impact of extraordinary or unusual
items, events or circumstances to avoid windfalls or hardships.
7.3 Form of Payment.
The
earned portion of a Stock Bonus may be paid currently or on a deferred basis
with such interest or dividend equivalent, if any, as the Committee may
determine. Payment may be made in the form of cash, whole Shares, including
Restricted Stock, or a combination thereof, either in a lump sum payment or
in
installments, all as the Committee will determine.
7.4 Termination During Performance Period.
If a
Participant is Terminated during a Performance Period for any reason, then
such
Participant will be entitled to payment (whether in Shares, cash or otherwise)
with respect to the Stock Bonus only to the extent earned as of the date of
Termination in accordance with the Performance Stock Bonus Agreement, unless
the
Committee determines otherwise.
8. PAYMENT FOR SHARE PURCHASES.
8.1 Payment.
Payment
for Shares purchased pursuant to this Plan may be made in cash (by check) or,
where expressly approved for the Participant by the Committee and where
permitted by law:
|
(a)
|
by
cancellation of indebtedness of the Company to the
Participant;
|
|
(b)
|
by
surrender of shares that either: (1) have been owned by Participant
for
more than six (6) months and have been paid for within the meaning
of SEC
Rule 144 (and, if such shares were purchased from the Company by
use of a
promissory note, such note has been fully paid with respect to such
shares); or (2) were obtained by Participant in the public
market;
|
|
(c)
|
subject
to applicable law, by waiver of compensation due or accrued to the
Participant for services rendered; provided,
that the portion of the Purchase Price equal to the par value of
the
Shares, if any, must be paid in
cash;
|
|
(d)
|
with
respect only to purchases upon exercise of an Option, and provided
that a
public market for the Company’s stock exists:
|
|
|
(1)
|
through
a "same day sale" commitment from the Participant and a broker-dealer
that
is a member of the National Association of Securities Dealers (an
"NASD Dealer")
whereby the Participant irrevocably elects to exercise the Option
and to
sell a portion of the Shares so purchased to pay for the Exercise
Price,
and whereby the NASD Dealer irrevocably commits upon receipt of such
Shares to forward the Exercise Price directly to the Company;
or
|
|
|
(2)
|
through
a "margin" commitment from the Participant and a NASD Dealer whereby
the
Participant irrevocably elects to exercise the Option and to pledge
the
Shares so purchased to the NASD Dealer in a margin account as security
for
a loan from the NASD Dealer in the amount of the Exercise Price,
and
whereby the NASD Dealer irrevocably commits upon receipt of such
Shares to
forward the Exercise Price directly to the Company;
or
|
|
(e)
|
by
any combination of the foregoing.
|
9. WITHHOLDING TAXES.
9.1 Withholding Generally.
Whenever Shares are to be issued in satisfaction of Awards granted under this
Plan, the Company may require the Participant to remit to the Company an amount
sufficient to satisfy federal, state and local withholding tax requirements
prior to the delivery of any certificate or certificates for such Shares.
Whenever, under this Plan, payments in satisfaction of Awards are to be made
in
cash, such payment will be net of an amount sufficient to satisfy federal,
state, and local withholding tax requirements.
9.2 Stock Withholding.
When,
under applicable tax laws, a Participant incurs tax liability in connection
with
the exercise or vesting of any Award that is subject to tax withholding and
the
Participant is obligated to pay the Company the amount required to be withheld,
the Committee may in its sole discretion allow the Participant to satisfy the
minimum withholding tax obligation by electing to have the Company withhold
from
the Shares to be issued that number of Shares having a Fair Market Value equal
to the minimum amount required to be withheld, determined on the date that
the
amount of tax to be withheld is to be determined. All elections by a Participant
to have Shares withheld for this purpose will be made in accordance with the
requirements established by the Committee and be in writing in a form acceptable
to the Committee.
10. PRIVILEGES OF STOCK OWNERSHIP.
10.1 Voting and Dividends.
No
Participant will have any of the rights of a shareholder with respect to any
Shares until the Shares are issued to the Participant. After Shares are issued
to the Participant, the Participant will be a shareholder and have all the
rights of a shareholder with respect to such Shares, including the right to
vote
and receive all dividends or other distributions made or paid with respect
to
such Shares; provided,
that if
such Shares are Restricted Stock, then any new, additional or different
securities the Participant may become entitled to receive with respect to such
Shares by virtue of a stock dividend, stock split or any other change in the
corporate or capital structure of the Company will be subject to the same
restrictions as the Restricted Stock; provided,
further,
that
the Participant will have no right to retain such stock dividends or stock
distributions with respect to Shares that are repurchased at the Participant's
original Purchase Price pursuant to Section 12.
10.2 Financial Statements.
If
expressly required by any state securities authorities as a condition of the
offer and issuance of Awards in compliance with the securities laws of such
state, the Company shall provide to each Participant during the period such
Participant holds an outstanding Award a copy of the financial statements of
the
Company as prepared either by the Company or independent certified public
accountants of the Company. Such financial statements shall be delivered as
soon
as practicable following the end of the Company's fiscal year during the period
Awards are outstanding; provided,
however,
the
Company will not be required to provide such financial statements to
Participants whose services in connection with the Company assure them access
to
equivalent information.
11. TRANSFERABILITY.
Unless
determined otherwise by the Committee, Awards granted under this Plan, and
any
interest therein, will not be transferable or assignable by Participant, and
may
not be made subject to execution, attachment or similar process, otherwise
than
by will or by the laws of descent and distribution. During the lifetime of
the
Participant, an Award will be exercisable only by the Participant, and any
elections with respect to an Award, may be made only by the Participant. If
the
Committee in its sole discretion makes an Award or any interest therein
transferable, such Award may only be transferred (i) by will, (ii) by the laws
of descent and distribution, or (iii) as permitted by Rule 701 of the Securities
Act.
12. RESTRICTIONS ON SHARES.
At the
discretion of the Committee, the Company may reserve to itself and/or its
assignee(s) in the Award Agreement a right to repurchase a portion of or all
Shares that are not "Vested" (as defined in the Stock Option Agreement) held
by
a Participant following such Participant's Termination at any time within ninety
(90) days after the later of Participant's Termination Date and the date
Participant purchases Shares under this Plan, for cash and/or cancellation
of
purchase money indebtedness, at the Participant's original Purchase Price,
provided, that the right to repurchase lapses at the rate of at least 20% per
year over five (5) years from the date the Shares were purchased (or from the
date of grant of options in the case of Shares obtained pursuant to a Stock
Option Agreement and Stock Option Exercise Agreement), and if the right to
repurchase is assignable, the assignee must pay the Company, upon assignment
of
the right to repurchase, cash equal to the excess of the Fair Market Value
of
the Shares over the original Purchase Price.
13. CERTIFICATES.
All
certificates for Shares or other securities delivered under this Plan will
be
subject to such stock transfer orders, legends and other restrictions as the
Committee may deem necessary or advisable, including restrictions under any
applicable federal, state or foreign securities law, or any rules, regulations
and other requirements of the SEC or any stock exchange or automated quotation
system upon which the Shares may be listed or quoted.
14. ESCROW.
To
enforce any restrictions on a Participant's Shares, the Committee may require
the Participant to deposit all certificates representing Shares, together with
stock powers or other instruments of transfer approved by the Committee,
appropriately endorsed in blank, with the Company or an agent designated by
the
Company, to hold in escrow until such restrictions have lapsed or terminated,
and the Committee may cause a legend or legends referencing such restrictions
to
be placed on the certificates.
15. REPRICING, EXCHANGE,
BUYOUT OF AWARDS.
The
repricing of Options is permitted without prior stockholder approval, provided
that the terms of the repricing satisfy the requirements of Section 409A of
the Code and any regulations or rulings promulgated by the Internal Revenue
Service. The Committee may, at any time or from time to time authorize the
Company, in the case of an Option exchange without stockholder approval, and
with the consent of the respective Participants, to issue new Awards in exchange
for the surrender and cancellation of any or all outstanding Awards. The
Committee may at any time buy from a Participant an Option previously granted
with payment in cash, Shares or other consideration, based on such terms and
conditions as the Committee and the Participant may agree.
16. SECURITIES LAW AND OTHER REGULATORY COMPLIANCE.
An
Award will not be effective unless such Award is in compliance with all
applicable federal and state securities laws, rules and regulations of any
governmental body, and the requirements of any stock exchange or automated
quotation system upon which the Shares may then be listed or quoted, as they
are
in effect on the date of grant of the Award and also on the date of exercise
or
other issuance. Notwithstanding any other provision in this Plan, the Company
will have no obligation to issue or deliver certificates for Shares under this
Plan prior to: (a) obtaining any approvals from governmental agencies that
the
Company determines are necessary or advisable; and/or (b) completion of any
registration or other qualification of such Shares under any state or federal
law or ruling of any governmental body that the Company determines to be
necessary or advisable. The Company will be under no obligation to register
the
Shares with the SEC or to effect compliance with the registration, qualification
or listing requirements of any state securities laws, stock exchange or
automated quotation system, and the Company will have no liability for any
inability or failure to do so.
17. NO OBLIGATION TO EMPLOY.
Nothing
in this Plan or any Award granted under this Plan will confer or be deemed
to
confer on any Participant any right to continue in the employ of, or to continue
any other relationship with, the Company or any Parent, Subsidiary or Affiliate
of the Company or limit in any way the right of the Company or any Parent,
Subsidiary or Affiliate of the Company to terminate Participant's employment
or
other relationship at any time, with or without cause.
18. CORPORATE TRANSACTIONS.
18.1 Assumption or Replacement of Awards by Successor.
In the
event of (a) a dissolution or liquidation of the Company, (b) a merger or
consolidation in which the Company is not the surviving corporation
(other than
a merger
or consolidation with a wholly-owned subsidiary, a reincorporation of the
Company in a different jurisdiction, or other transaction in which there is
no
substantial change in the shareholders of the Company or their relative stock
holdings and the Awards granted under this Plan are assumed, converted or
replaced by the successor corporation, which assumption will be binding on
all
Participants), (c) a merger in which the Company is the surviving corporation
but after which the shareholders of the Company immediately prior to such merger
(other than any shareholder which merges (or which owns or controls another
corporation which merges) with the Company in such merger) cease to own their
shares or other equity interests in the Company, (d) the sale of substantially
all of the assets of the Company, or (e) any other transaction which qualifies
as a "corporate transaction" under Section 424(a) of the Code wherein the
shareholders of the Company give up all of their equity interest in the Company
(except
for the
acquisition, sale or transfer of all or substantially all of the outstanding
shares of the Company from or by the shareholders of the Company), any or all
outstanding Awards may be assumed, converted or replaced by the successor
corporation (if any), which assumption, conversion or replacement will be
binding on all Participants. In the alternative, the successor corporation
may
substitute equivalent Awards or provide substantially similar consideration
to
Participants as was provided to shareholders (after taking into account the
existing provisions of the Awards). The successor corporation may also issue,
in
place of outstanding Shares of the Company held by the Participant,
substantially similar shares or other property subject to repurchase
restrictions no less favorable to the Participant. In the event such successor
corporation (if any) refuses to assume or substitute such Awards, as provided
above, pursuant to a transaction described in this Subsection 18.1, such Awards
shall expire on such transaction at such time and on such conditions as the
Board will determine. Notwithstanding anything in this Plan to the contrary,
the
Board may, in its sole discretion, provide that the vesting of any or all Awards
granted pursuant to this Plan will accelerate upon a transaction described
in
this Section 18. If the Board exercises such discretion with respect to
Options, such Options will become exercisable to the extent determined by the
Board prior to the consummation of such event at such time and on such
conditions as the Board determines, and if such Options are not exercised prior
to the consummation of the corporate transaction, they shall terminate at such
time as determined by the Board.
18.2 Other Treatment of Awards.
Subject
to any greater rights granted to Participants under the foregoing provisions
of
this Section 18, in the event of the occurrence of any transaction described
in
Section 18.1, any outstanding Awards will be treated as provided in the
applicable agreement or plan of merger, consolidation, dissolution, liquidation,
sale of assets or other "corporate transaction."
18.3 Assumption of Awards by the Company.
The
Company, from time to time, also may substitute or assume outstanding awards
granted by another company, whether in connection with an acquisition of such
other company or otherwise, by either; (a) granting an Award under this Plan
in
substitution of such other company's award; or (b) assuming such award as if
it
had been granted under this Plan if the terms of such assumed award could be
applied to an Award granted under this Plan. Such substitution or assumption
will be permissible if the holder of the substituted or assumed award would
have
been eligible to be granted an Award under this Plan if the other company had
applied the rules of this Plan to such grant. In the event the Company assumes
an award granted by another company, the terms and conditions of such award
will
remain unchanged (except
that the
exercise price and the number and nature of Shares issuable upon exercise of
any
such option will be adjusted appropriately pursuant to Section 424(a) of the
Code). In the event the Company elects to grant a new Option rather than
assuming an existing option, such new Option may be granted with a similarly
adjusted Exercise Price.
19. ADOPTION AND SHAREHOLDER
APPROVAL.
This
Plan was adopted by the Board on May 26, 2005 (“Effective
Date”).
This
Plan shall be approved by the shareholders of the Company (excluding Shares
issued pursuant to this Plan), consistent with applicable laws, within twelve
(12) months after the Effective Date. Upon the Effective Date, the Board may
grant Awards pursuant to this Plan; provided,
however,
that:
(a) no Option may be exercised prior to initial shareholder approval of this
Plan; (b) no Option granted pursuant to an increase in the number of Shares
subject to this Plan approved by the Board will be exercised prior to the time
such increase has been approved by the shareholders of the Company; and (c)
in
the event that shareholder approval of such increase is not obtained within
the
time period provided herein, all Awards granted hereunder will be canceled,
any
Shares issued pursuant to any Award will be canceled, and any purchase of Shares
hereunder will be rescinded.
20. TERM OF PLAN.
Unless
earlier terminated as provided herein, this Plan will terminate ten (10) years
following the Effective Date.
21. AMENDMENT OR TERMINATION OF PLAN.
The
Board may at any time terminate or amend this Plan in any respect, including
without limitation amendment of any form of Award Agreement or instrument to
be
executed pursuant to this Plan. Notwithstanding the foregoing, neither the
Board
nor the Committee shall, without the approval of the shareholders of the
Company, amend this Plan in any manner that requires such shareholder approval
pursuant to the Code or the regulations promulgated thereunder as such
provisions apply to ISO plans or (if the Company is subject to the Exchange
Act)
pursuant to the Exchange Act or any rule promulgated thereunder. In addition,
no
amendment that is detrimental to a Participant may be made to any outstanding
Award without the consent of the Participant.
22. NONEXCLUSIVITY OF THE PLAN.
Neither
the adoption of this Plan by the Board, the submission of this Plan to the
shareholders of the Company for approval, nor any provision of this Plan will
be
construed as creating any limitations on the power of the Board to adopt such
additional compensation arrangements as it may deem desirable, including,
without limitation, the granting of stock options and bonuses otherwise than
under this Plan, and such arrangements may be either generally applicable or
applicable only in specific cases.
23. LIMITATION.
If
expressly required by one or more state securities authorities or laws as a
condition of issuing Awards and Shares in compliance with the securities laws
of
such state, the Company will not issue any Awards or Shares under this Plan
without first obtaining shareholder approval of this Plan in such manner as
required by the applicable state securities authorities or laws.
24. DEFINITIONS.
As used
in this Plan, the following terms will have the following meanings:
"Affiliate"
means
any corporation that directly, or indirectly through one or more intermediaries,
controls or is controlled by, or is under common control with, another
corporation, where "control" (including the terms "controlled by" and "under
common control with") means the possession, direct or indirect, of the power
to
cause the direction of the management and policies of the corporation, whether
through the ownership of voting securities, by contract or
otherwise.
"Award"
means
any award under this Plan, including any Option, Restricted Stock or Stock
Bonus.
"Award Agreement"
means,
with respect to each Award, the signed written agreement between the Company
and
the Participant setting forth the terms and conditions of the
Award.
"Board"
means
the Board of Directors of the Company.
“Cause”
means
termination of the Participant’s employment on the basis of the Participant’s
conviction (or a plea of nolo
contendere)
of
fraud, misappropriation, embezzlement or any other act or acts of dishonesty
constituting a felony and resulting or intended to result directly or indirectly
in a substantial gain or personal enrichment to the Participant at the expense
of the Company or any Subsidiary.
"Code"
means
the Internal Revenue Code of 1986, as amended.
"Committee"
means
the committee appointed by the Board to administer this Plan, or if no such
committee is appointed, the Board.
"Company"
means
NutraCea, a corporation organized under the laws of the State of California,
or
any successor corporation.
"Disability"
means a
disability, whether temporary or permanent, partial or total, as determined
by
the Committee.
"Exchange Act"
means
the Securities Exchange Act of 1934, as amended.
"Exercise Price"
means
the price at which a holder of an Option may purchase the Shares issuable upon
exercise of the Option.
“Fair
Market Value”
means,
as of any date, the value of a share of the Company’s Common Stock determined as
follows:
(1) if
such
Common Stock is then quoted on the Nasdaq Global Select Market, the Nasdaq
Global Market or the Nasdaq Capital Market (collectively, the “Nasdaq Market”)
or the OTC Bulletin Board, its closing price on the Nasdaq Market or the OTC
Bulletin Board on the date of determination, or if there are no sales for such
date, then the last preceding business day on which there were sales, as
reported in The Wall Street Journal or such other source as the Board or the
Committee deems reliable;
(2) if
such
Common Stock is publicly traded and is then listed on a national securities
exchange, its closing price on the date of determination on the principal
national securities exchange on which the Common Stock is listed or admitted
to
trading as reported in The Wall Street Journal or such other source as the
Board
or the Committee deems reliable;
(3) if
such
Common Stock is publicly traded but is neither quoted on the Nasdaq Market,
listed or admitted to trading on a national securities exchange, nor trading
on
the OTC Bulletin Board, the average of the closing bid and asked prices on
the
date of determination as reported in The Wall Street Journal or such other
source as the Board or the Committee deems reliable; or
(4) if
none
of the foregoing is applicable, by the Board or the Committee in good faith
and
by taking into account such factors as may be required by applicable
law.
"Insider"
means an
officer or director of the Company or any other person whose transactions in
the
Company's Common Stock are subject to Section 16 of the Exchange
Act.
“Non-employee
Director”
means a
director who either (i) is not a current employee or officer of the Company
or
an Affiliate, does not receive compensation, either directly or indirectly,
from
the Company or an Affiliate for services rendered as a consultant or in any
capacity other than as a director (except for an amount as to which disclosure
would not be required under Item 404(a) of Regulation S-K promulgated pursuant
to the Securities Act (“Regulation
S-K”)),
does
not possess an interest in any other transaction for which disclosure would
be
required under Item 404(a) of Regulation S-K, and is not engaged in a business
relationship for which disclosure would be required pursuant to Item 404(b)
of
Regulation S-K; or (ii) is otherwise considered a “non-employee director” for
purposes of Rule 16b-3.
"Option"
means an
award of an option to purchase Shares pursuant to Section 5.
"Parent"
means
any corporation (other than the Company) in an unbroken chain of corporations
ending with the Company, if at the time of the granting of an Award under this
Plan, each of such corporations other than the Company owns stock possessing
50%
or more of the total combined voting power of all classes of stock in one of
the
other corporations in such chain.
"Participant"
means a
person who receives an Award under this Plan.
"Plan"
means
this NutraCea 2005 Equity Incentive Plan, as amended from time to
time.
"Restricted Stock Award"
means an
award of Shares pursuant to Section 6.
"SEC"
means
the Securities and Exchange Commission.
"Securities Act"
means
the Securities Act of 1933, as amended.
"Shares"
means
shares of the Company's Common Stock reserved for issuance under this Plan,
as
adjusted pursuant to Sections 2 and 18, and any successor security.
"Stock Bonus"
means an
award of Shares, or cash in lieu of Shares, pursuant to Section 7.
"Subsidiary"
means
any corporation (other than the Company) in an unbroken chain of corporations
beginning with the Company if, at the time of granting of the Award, each of
the
corporations other than the last corporation in the unbroken chain owns stock
possessing 50% or more of the total combined voting power of all classes of
stock in one of the other corporations in such chain.
"Termination"
or
"Terminated"
means,
for purposes of this Plan with respect to a Participant, that the Participant
has for any reason ceased to provide services as an employee, director,
consultant or advisor to the Company or a Parent, Subsidiary or Affiliate of
the
Company, except
in the
case of sick leave, military leave, or any other leave of absence approved
by
the Committee, provided that such leave is for a period of not more than ninety
(90) days, or reinstatement upon the expiration of such leave is guaranteed
by
contract or statute. The Committee will have sole discretion to determine
whether a Participant has ceased to provide services and the effective date
on
which the Participant ceased to provide services (the "Termination Date").
End
of Plan
Annex
E
Form
of Amendment to NutraCea's Articles of Incorporation
Article
Three of the Articles of Incorporation of the Corporation shall be amended
to
read in full as follows:
“This
Corporation is hereafter authorized to issue two (2) classes of shares of
stock
designated respectively “Common Stock” and “Preferred Stock.” The total number
of shares of Common Stock that this Corporation is authorized to issue is
three
hundred fifty million (350,000,000) and the total number of shares of Preferred
Stock that this Corporation is authorized to issue is twenty million
(20,000,000).
The
Preferred Stock may be divided into such number of series as the board of
directors may determine. The board of directors is authorized to determine
and
alter the rights, preferences, privileges and restrictions granted to or
imposed
upon any wholly unissued series of Preferred Stock, and to fix the number
of
shares of any series of Preferred Stock and the designation of any such series
of Preferred Stock. The board of directors, within the limits and restrictions
stated in any resolution or resolutions of the board of directors originally
fixing the number of shares constituting any series, may increase or decrease
(but not below the number of shares of such series then outstanding) the
number
of shares of any series subsequent to the issue of shares of that
series.”
Annex
F
Form
of Amendment to NutraCea’s Bylaws
Article
II, Section 10 of the NutraCea’s Bylaws is amended in its entirety to read as
follows:
“SECTION
10. Voting.
The
shareholders entitled to vote at any meeting of shareholders shall be determined
in accordance with the provisions of ARTICLE II, Section 6, subject to the
provisions of Sections 702 to 704, inclusive, of the California Corporations
Code (relating to voting shares held by a fiduciary, in the name of a
corporation or in joint ownership). The shareholders' vote may be by voice
vote
or by ballot; provided, however, that any election for directors must be by
ballot if demanded by any shareholder before the voting has begun. In the
absence of any contrary provision in the articles of incorporation of the
corporation or in any applicable statute relating to the election of directors
or to other particular matters, each such person shall be entitled to one vote
for each share. On any matter other than election of directors, any shareholder
may vote part of the shares in favor of the proposal and refrain from voting
the
remaining shares or vote them against the proposal, but, if the shareholder
fails to specify the number of shares which the shareholder is voting
affirmatively, it will be conclusively presumed that the shareholder's approving
vote is with respect to all shares that the shareholder is entitled to vote.
The
affirmative vote of a majority of the shares represented and voting at a duly
held meeting at which a quorum is present (which shares voting affirmatively
also constitute a majority of the required quorum) shall be the act of the
shareholders, unless the vote of a greater number or voting by classes is
required by the California Corporations Code or the articles of incorporation
of
the corporation.
No
shareholder entitled to vote at any election of directors shall be entitled
to
cumulate votes for candidates in nomination either (i) by giving one candidate
a
number of votes equal to the number of directors to be elected multiplied by
the
number of votes to which that shareholder's shares are normally entitled or
(ii)
by distributing the shareholder's votes on the same principle among any or
all
of the candidates, as the shareholder thinks fit. This paragraph shall become
effective only when the corporation becomes a "listed corporation" within the
meaning of Section 301.5 of the California Corporations Code. This paragraph
may
not be modified, amended, rescinded or repealed except by a duly adopted
amendment to the articles of incorporation or by an amendment to this bylaw
duly
adopted by the vote or written consent of the holders of a majority of the
outstanding shares entitled to vote.”